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Abstract
In the research described in this thesis, the intestinal microbiota of healthy subjects was 
characterized in detail and benchmarked against two perturbations, bowel cleansing and irritable 
bowel syndrome, both hypothesized to alter the microbial composition. First, four commonly 
used faecal DNA extraction protocols were compared to determine the optimal method to be 
utilized in all of the following projects. Th e extraction of DNA from faecal samples is a crucial 
step in molecular analyses as incomplete cell lysis of certain members of the diverse intestinal 
ecosystem can bias the resultant community composition. We detected performance diff erences 
between the mechanical and enzymatic methods as well as with commercial kits. Th e DNA yields 
varied by 35-fold, moreover the abundance and diversity of diff erent bacterial groups were found 
to be signifi cantly diff erent between the extraction methods. Th e levels of certain Firmicutes 
and Archaea were on average 20-fold lower with the tested commercial kit as compared to the 
method with a mechanical lysis step that also effi  ciently disrupted the more diffi  cult-to-lyse 
Gram positive and Archaeal cell walls. Th e best performing method involved mechanical lysis 
based on repeated bead-beating and thus this was utilized in the subsequent studies. 
To identify alterations in the microbiota of patients, it is essential to characterize microbiota 
of healthy subjects. Hence, the intestinal microbiota of healthy adults and specifi cally its temporal 
stability were investigated. Moreover, the commonly shared, the core microbiota as well as the 
relation of intestinal symptoms and microbiota composition were addressed; fi rst by performing 
a longitudinal study, which monitored a group of 15 healthy Finnish subjects for seven weeks 
and regularly assessed their intestinal bacteria. Additionally, the participants’ perception of 
health and the occurrence of intestinal symptoms were recorded with a questionnaire at each 
sampling point. Th e healthy microbiota was characterized as displaying high subject-specifi city 
and temporal stability. Approximately 35% of the detected bacterial phylotypes were detected 
in all participants, emphasizing their contribution to the core microbiota. Moreover, signifi cant 
correlations between the microbiota and mild intestinal symptoms were identifi ed, including 
abdominal pain and bloating; these symptoms were correlated to the scarcity of bifi dobacteria. 
Th is study provided the baseline data of the microbiota of healthy adults and thus can be used in 
further work aimed at benchmarking perturbations. 
Adequate bowel cleansing such as used prior to colonoscopy or gastric surgery has been 
shown to be safe for patients. However, the long-term eff ects of the use of purgatives on the 
intestinal microbiota, and especially the potential diff erences arising from diff erent dosing 
regimens have not been addressed previously. We found that in healthy adults the intestinal 
microbiota was generally resilient to purging with the tested osmotic laxative, and the majority 
of the bacterial levels that changed, returned to the subject’s baseline already two weeks aft er 
the lavage. However, the rate of recovery was dependent on the dosing of the purgative, since 
the consumption of a single dose of the purgative had a more severe and long-lasting eff ect 
on the microbiota composition than the split dose. Moreover, bacterial phylotypes belonging 
to Proteobacteria, a phylum that contains potential pathogens, were increased in the group 
consuming a single dose of the purgative. It was concluded that the use of two separate doses 
of the purgative resulted in fewer changes in the intestinal microbiota than a single dose and 
therefore should be preferred in the clinical practice. 
Th ere is growing evidence of the involvement of the intestinal microbiota in the 
pathophysiology of irritable bowel syndrome (IBS). However, the microbial component in post-
infectious (PI) IBS patients has previously remained uncharacterised. Th e spectrum of symptoms 
in PI-IBS is heterogeneous and in parallel to the characterization of intestinal microbiota of 
post-infectious patients and its comparison with other IBS patients, one aim of this work was to 
address the associations between the intestinal microbiota and a patient’s clinical characteristics. 
We identifi ed a bacterial signature, consisting of 27 genus-like bacterial taxa that separated 
the healthy controls from PI-IBS and other IBS patients. Th e diff erences mainly consisted 
of increased levels of Bacteroidetes as well as uncultured members of the Clostridia that were 
decreased in the patients. Th e abundances of these bacteria correlated with clinical markers and 
expression levels of several host gene pathways, including amino acid synthesis, cell junction 
integrity and infl ammatory response, all suggesting an impaired epithelial barrier function in 
IBS. Identifi cation of these specifi c associations between the host and intestinal microbiota may 
provide novel insights into the origin and mechanistic background of intestinal symptoms in IBS 
as well as enables novel stratifi cation of the IBS patient material with a diff erent aetiology.
In conclusion, this thesis characterised the normal healthy intestinal microbiota and how 
perturbations such as IBS and bowel cleansing can disrupt the microbial composition. Th e 
results have clinical relevance by providing novel and a much needed tool for segregating the IBS 
patient material objectively as well as providing grounds for choosing the split-dosing regime of 
the purgative agent as an optimal bowel cleansing method. Furthermore, associations between 
the microbiota and health markers of the host were detected that will give grounds for future 
research on the aetiology of IBS. Finally, we determined and validated an optimal faecal DNA 
extraction method.
11.  INTRODUCTION
Th e human gastrointestinal (GI) microbiota is a complex ecosystem harbouring trillions of 
organisms, mainly bacteria but also viruses and eukaryotic organisms. It is estimated that 
the intestinal microbiota contains 1014 bacterial cells, outnumbering the host cells by ten-
fold. Moreover, the genetic potential of the intestinal microbiome, the collective genome of 
the microbiota, is 100-fold greater than that of the human genome (Bäckhed et al., 2005; 
Huttenhower et al., 2012; Ley et al., 2006a; Qin et al., 2010). Unlike our own genome, the 
intestinal microbiome is not only vertically transmitted and fi xed, but can be modifi ed by early 
life events, diet and pharmaceutical treatments that aff ect the composition, stability and function 
of the gut ecosystem.
Th e co-evolution between the host and microbiota has resulted into a mutually benefi cial 
relationship in which gut bacteria make essential contributions to human health e.g. by 
producing benefi cial metabolites and vitamins and in return are allowed to occupy a nutrient-
rich environment (Salonen and de Vos, 2014). Th e microbiota is also involved in the maturation 
of the immune system (Nylund et al., 2014) and in regulation of innate and adaptive immune 
responses (Maynard et al., 2012), for instance via initiation of specifi c T cell responses (Round et 
al., 2011). Although the mucosal barrier, which consists of the mucus layer and epithelial cells, 
prevents direct contact with the intestinal bacteria, there is constant cross-talk between the two 
systems allowing mutual benefi ts.
Additionally, there is growing evidence to indicate that the intestinal microbiota, and its 
alterations that are referred to as dysbiosis, may be an important factor in the pathogenesis of 
various diseases. Compositional changes in the microbiota have been associated with several 
conditions ranging from disorders limited to the GI tract, such as IBS, to systemic diseases, such 
as diabetes (de Vos and de Vos, 2012). In many cases, the implicated microbiological and host-
microbe interaction processes are only beginning to be understood, making the research in this 
fi eld pivotal in achieving a better understanding of human health.
It is important to characterize the microbial composition and function in a healthy host 
before understanding how the dysbiosis might aff ect pathogenesis of the related diseases. Th e 
aim of this doctoral thesis was to study what typifi es a normal, healthy intestinal microbiota, and 
how the microbiota would be altered by a common medical procedure, bowel cleansing, as well 
as gastroenteritis-provoked IBS. In addition to the microbiological changes, the associations of 
the microbiota with subjective and objective host parameters, including occurrence of intestinal 
symptoms and clinical laboratory tests, were investigated.   
Introduction
22.  REVIEW OF THE LITERATURE
2.1  AN OVERVIEW OF THE MOLECULAR METHODS USED TO STUDY THE 
INTESTINAL MICROBIOTA 
Much of the current knowledge on the diversity of the intestinal microbiota has been dependent 
on the development of high-throughput technologies, most of which are based on the analysis 
of the small sub-unit ribosomal 16S rRNA gene, as a tool to classify the diff erent microbial 
phylotypes. Th is gene is present in all bacteria and it contains both conserved and variable 
regions that allow taxonomic identifi cation of bacterial species (Woese, 1987). To date, over 1000 
diff erent bacterial species residing in the human gastrointestinal tract have been characterised 
with cultivation (Rajilic-Stojanovic and de Vos, 2014). However, the majority of intestinal 
bacteria have been characterized only by their 16S rRNA gene sequence and therefore the 
function and relevance of these uncultured phylotypes remain unresolved. With the aid of high-
throughput techniques, over 3000 gut-derived prokaryotes have been recognized and 9.8 million 
bacterial genes identifi ed from the intestines of healthy adults, increasing our understanding of 
the bacterial diversity and its relation with health and disease (Li et al., 2014). 
Achieving access to the genomic potential of the intestinal microbiota requires collecting of 
the bacteria and disrupting the cells. Faecal samples are the most widely used material, due to their 
easy and non-invasive access, while biopsies from the intestinal wall are occasionally sampled. 
Th e high microbial diversity in the faecal sample as well as the complexity and heterogeneity of 
the starting material makes the study of intestinal microbiota challenging. Although the major 
fl aws in the pre-analytical steps typically originate from incomplete or biased DNA extraction, 
also other factors, such as storage conditions, can aff ect the microbial composition. Th e optimal 
preservation conditions for stool samples prior to DNA extraction is that they should be kept 
at room temperature for maximum of 24 h prior to DNA extraction. Alternatively the samples 
could be placed immediately aft er collection at −20°C and stored at –80°C for longer periods 
of time (Cardona et al., 2012). Freezing of the faecal sample prior to the DNA extraction has 
been shown to aff ect the Firmicutes/Bacteroidetes ratio, in most cases signifi cantly by lowering 
the Bacteroides proportion signifi cantly (Bahl et al., 2012). However, extracting DNA from fresh 
samples is diffi  cult to perform in large-scale studies, and most of the published work has been 
conducted from frozen samples.
2.1.1  DNA EXTRACTION
Th e majority of the molecular studies, which have attempted to characterize microbial 
communities, have been based on the analysis of DNA. Th erefore, the quality of the work is 
largely dependent on the effi  ciency of the faecal DNA extraction protocol. Large species diversity 
poses major challenges to the DNA extraction methods, especially because cell wall structures 
and thus their propensity to lyse vary among the microbiota. Th e fi eld is currently lacking any 
standard operating procedures for DNA extraction, and the use of several diff erent methods 
complicates the comparison of individual studies. Th e protocols of all DNA extraction methods 
have two main objectives, disruption the bacterial cell wall followed by recovery of the DNA. Th e 
key points of both of the steps will be detailed below. 
Th e two major bacterial phyla of the intestinal microbiota, Gram-positive Firmicutes and 
Gram-negative Bacteroidetes have very diff erent cell wall structures, hence they diff er in the 
optimal DNA extraction methods. Th e lysis of the Gram-positive bacteria requires a rigorous 
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3extraction method, which poses the risk that this group will be underrepresented in the resultant 
community structure due to failure to lyse the bacterial cells. Th e Gram-negative bacteria lyse 
more easily due to their thinner peptidoglycan cell wall but if an excessively harsh extraction 
protocol is applied, this may result in degraded DNA and lower diversity and abundance of these 
bacteria. Such pronounced diff erences in the bacterial cell wall properties of the mixed community, 
and the challenges posed by the starting material (i.e. presence of inhibitors, variability of 
the matrix, heterogeneity of the sample) places limits on the ability to collect a representative 
sample of the faecal microbiota. Th erefore, it is unlikely that one can develop a completely 
unbiased DNA extraction method. Th e majority of the utilized protocols rely on mechanical, 
enzymatic or chemical disruption of the cell wall, or a combination of these procedures. Th ere 
have been several studies, including Study I in this thesis, which have attempted to compare 
the available faecal extraction methods. Th eir results clearly indicate that the combination of 
mechanical procedures, typically achieved by bead-beating, with either chemical or enzymatic 
lysis is the most eff ective way to acquire a holistic view of the microbiota (Claassen et al., 2013; 
Maukonen et al., 2012; Yuan et al., 2012). For example the numbers of bifi dobacteria are shown 
to be reduced in DNA extracts lacking the mechanical lysis step (Claassen et al., 2013; Santiago 
et al., 2014b). Mechanical cell disruption can be achieved in several diff erent ways, including 
sonication. Perhaps the most common protocol utilizes the combination of lysis buff er and small 
beads (typically 0.1 mm in diameter) that are added to the faecal material and shaken extensively 
in order to break the cell wall structures, although this can result in fragmentation of DNA. 
Th erefore, when the methods used in research requires the extracted DNA to be intact or in as 
large fragments as possible  (e.g. followed by %GC-profi ling or large DNA libraries), vigorous 
mechanical lysis protocols are not suitable. In these cases, the preferred DNA extraction protocol 
is usually based on diff erential centrifugation and lysis (Apajalahti et al., 1998) or chemical 
and enzymatic disruption of the cells (Ahlroos and Tynkkynen, 2009). However, most of the 
current next generation sequencing (NGS) methods fragment the target DNA and therefore 
do not require the presence of large intact DNA molecules. When using chemical or enzymatic 
lysis, diff erent organic solvents (e.g. methanol), detergents (e.g. sodium dodecyl sulfate, SDS) 
or enzymes (e.g. lysozyme) are used with the aim being to disrupt the cell walls of both Gram-
negative and -positive bacteria. Th is approach results in less fragmented DNA, but due to the 
large variations in the properties of the outer cell surface structure, there is a greater risk of bias 
towards accessing only the easily breakable bacterial cells. 
While the incomplete disruption of the cell wall of the community members can introduce 
a selective bias, the following steps of the DNA extraction protocols (removal of inhibitors, RNA 
and proteins as well as collection of DNA) are not thought to be biased towards any specifi c 
bacterial group. However, those procedures may aff ect the yield and quality of the collected 
DNA, which in turn can impact the success of the downstream applications, such as PCR. It has 
been shown that DNA extraction methods using phenol-chloroform purifi cation and ethanol 
precipitation will harvest relatively more bacterial DNA than DNA extraction methods based on 
silica columns for DNA recovery (Study I, Morita et al., 2007).
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4Table 1: Overview of the analytical methods used to study the intestinal microbiota community.
Technique 16S rDNA based Sensitivity Advantages Limitations
Culturing No Moderate
Ability to gain functional 
information from the or-
ganism and to characterise 
novel species
Labour intensive, most of the 
intestinal microbiota cannot 
yet be cultured
FISHa Yes Good
Targets bacterial taxa at 
both the species and group 
level. Enumeration of bac-
teria not dependent on 16S 
copy number
No novel taxa identifi ed. Re-
quires reference strains for 
validation. Laborious. Detec-
tion not at the community 
level
qPCR Yes Good Detection of both specifi c or higher bacterial taxa
Labour intensive for larger 
validation, requires reference 
strains for the quantitative 
analysis. 16S copy number 
varies Detection not at the 
community level
DGGEb Yes Poor
Provides a snapshot of 
the predominant bacterial 
species in an ecosystem, 
fast and inexpensive 
Poor reproducibility and sen-
sitivity
Phylogenetic 
microarrays Yes Good
Fast and deep detection of 
intestinal microbiota sam-
ples based on previously 
known sequences
No novel phylotypes detected
Next generation 
sequencing Yes Good
High-throughput, detects 
novels species
Requires extensive bioinfor-
matical analysis, PCR chimera 
represents the most relevant 
bias
Metagenomics Genome-wide Good
Ability to gain information 
on both the composition 
and genetic potential of the 
intestinal microbiota com-
munity. High-throughput, 
detects novel genomes
Requires extensive bioinfor-
matical analysis. Annotation 
limited by the available refer-
ence genomes and hence lim-
ited phylogenetic information. 
Activity of genetic potential 
cannot be addressed
aFISH = Fluorecent in situ hybridization
bDGGE = Denaturing gradient gel electrophoresis
2.1.2  MOLECULAR METHODS FOR ANALYSING THE INTESTINAL MICROBIOTA 
COMMUNITY 
Th e methods used for the microbiota analysis depend on the research question and the project 
framework. Table 1 provides an overview of the most commonly used analytical techniques; 
high-throughput methods for the microbial community analysis, namely NGS and phylogenetic 
microarrays, will be discussed in more detail below.
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Microarrays were originally developed for the detection of diff erences in the expression of 
eukaryotic or prokaryotic genes. However, currently the technique is also implemented in the 
characterization of the microbial communities within the intestine (Brodie et al., 2006; Kang et 
al., 2010; Manges et al., 2010; Paliy et al., 2009; Palmer et al., 2007; Rajilic-Stojanovic et al., 2009; 
Tottey et al., 2013; Wang et al., 2004). Th e analysis pipeline includes a universal PCR targeting 
the conserved regions of 16S rRNA to achieve high primer coverage of all bacteria. As with all 
PCR based techniques, the choice of universal primers and the amplifi cation bias will aff ect the 
detected phylotypes (Lee et al., 2012).  It is now well established that there is no truly universal 
primers that would equally amplify all bacterial sequences. Th is limitation aff ects all techniques 
based on detection of PCR amplifi ed 16S rRNA gene sequences, including NGS approaches 
(Frank et al., 2008; Huws et al., 2007). Although phylogenetic microarrays are semi-quantitative, 
and posses both a high analytical depth and high-throughput capability, the drawback of this 
technique is that no novel sequences can be detected. Additionally, the initial development of a 
phylogenetic microarray is technically demanding and requires extensive testing, optimization 
and validation. Nevertheless, the advantage of this method is its rapid capability to process 
samples and the bioinformatic requirements are considerably lower than encountered with the 
high-throughput NGS techniques. Moreover, the reproducibility of phylogenetic microarray 
protocol is high, allowing the identifi cation of even small biological diff erences. 
Th e phylogenetic microarray used in this thesis, the Human Intestinal Track Chip 
(HITChip), is based on oligonucleotide probes that have been designed from human gut-derived 
bacterial sequences gathered from the sequence databases (Rajilic-Stojanovic et al., 2009). Th e 
HITChip allows deep and accurate detection of up to 1140 species-level phylotypes on a highly 
reproducible manner (Study I, Rajilic-Stojanovic et al., 2009), allowing the detection of one of 
the larges collection of intestinal bacterial phylotypes. Only the recently developed HuGChip 
(Tottley et al., 2013) exceeds in the amount of detected phylotypes. Moreover, the method has 
been benchmarked and validated against pyro-sequencing (Claesson et al., 2009; van den Bogert 
et al., 2011), showing that the HITChip results can be replicated with other high-throughput 
methods. Th e data gathered from HITChip, so far over 6000 samples, is stored into a MySQL 
database, and represents a unique set of highly comparable data due to standardized analysis 
pipeline from the sample handling to analytical steps and data mining. Th is represents the largest 
existing data set of intestinal microbiota samples that have gone through the same preanalytical 
pipeline. Th e analysis of HITChip data is conducted with custom made scripts developed for 
this platform (Salojarvi and Lahti, 2014). To date, there has been 38 publications utilizing the 
HITChip microarray, including characterization of the microbiota in various disease states such 
as obesity (Verdam et al., 2013) and celiac disease (Cheng et al., 2013) as well as in diff erent age 
groups such as preterm noenates (Moles et al., 2013), pre-school children (Ringel-Kulka et al., 
2013), adults (Lahti et al., 2013) and elderly (Biagi et al., 2010). Th e large database collection 
provides an opportunity to unique meta-analysis of the intestinal microbiota, giving insight to 
its general features, such as the abundance distributions of diff erent bacterial groups (Lahti et al., 
2014) or the specifi cations of the core microbiota (Salonen et al., 2012).
NEXT GENERATION SEQUENCING
Th e NGS methods have dominated the microbiota research in recent years; the diff erent 
platforms are detailed in Table 2 (NGS methods also reviewed in Liu et al., 2012; Quail et al., 
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62012; Weinstock, 2012). NGS based techniques can be either used to sequence the variable 
regions of choice of the 16S rRNA gene, or metagenomic fragments (shotgun sequencing). In 
compositional microbiota analysis, the sequencing is preceded with a PCR amplifi cation of the 
16S rRNA gene, which introduces the same PCR biases as discussed before. Only the PacBio 
sequencing platform can be utilized without any prior PCR amplifi cation as it targets single 
molecules. Th e majority of the microbiota research utilising the NGS has been performed with 
the 454-platform. Large scale studies such as the US based Human Microbiome project (HMP), 
sampling 242 healthy adults at 15 or 18 body sites, have utilised this sequencing method (Methe 
et al., 2012). Th e other, European based large sequencing eff ort, metagenomics of the human 
intestinal tract (MetaHIT), utilised the lllumina Genome Analyser sequencing producing 
slightly shorter but many more sequencing reads than the 454, and provided the fi rst large-scale 
metagenomic reference dataset of 3.3 M microbial genes (Qin et al., 2010). Today, NGS allows 
cost-eff ective and deep sampling of large cohorts, but the post-analytical burden, removal of 
chimeras, sequencing errors and sequence alignment, is higher than what is encountered for 
instance with phylogenetic microarrays. However, the price of sequencing has rapidly decreased 
due to the development of new techniques, meaning that the sequencing will become an even 
more favourable technique in the future. Several bioinformatic pipelines have been developed 
for analysing NGS reads of the 16S rRNA gene, including MOTHUR (Schloss et al., 2009) and 
QIIME (Caporaso et al., 2010), making the accumulating sequencing data more comparable 
when such pipelines are utilized.
Table 2: Overview of the next generation sequencing (NGS) methods.
Platform Read length Reads per run Advantages Disadvantages
Sanger-
sequencing 750 bp  - Long reads, high accuracy
Slow, not high-throughput, 
requires biased clone librar-
ies
454 (Roche) 700 bp 1 mil
Long reads allows good cover-
ing several variable regions of 
16S rRNA in a single run
Chimeras. Runs are expen-
sive. Homopolymer errors
MiSeq 
(Illumina)  200 bp 40 mil High coverage and low cost Short reads and chimeras
SOLiD (Life 
technologies 
Th ermo)
75 + 35 bp 1.2 bil Low cost per base
Short sequence fragments. 
Slower than other methods. 
Not good coverage of palin-
dromic sequence
Ion-Torrent 400 bp 80 mil Uses pH changes for detections, fast performance
Chimeras, Homopolymer 
errors
PacBio 1kb - 30kb 50 000
Single molecule sequence tech-
nology based on visualization of 
each of the fl uorescence labelled 
nucleotide. No PCR required, 
High accuracy and long read 
lengths and fast
High sensitivity to contam-
inants and hence bias. Need 
for long DNA fragments. 
Moderate throughput. 
Equipment can be very ex-
pensive
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72.2  GASTROINTESTINAL MICROBIOTA IN HEALTHY SUBJECTS
Th e 7-meter long GI tract varies greatly in terms of its microbial diversity and composition 
(Figure 1). Th e bacterial load increases and the oxygen levels declines towards the distal parts 
of the digestive tract, while the pH rises from acidic towards neutrality. Th e intestinal tract can 
be divided into the lumen, containing the indigested foods and the bulk of microbes, and the 
mucosal layers with its attached microbiota. Due to the large amount of bacteria inhabiting 
the human GI tract, the colonic epithelium is essential in the successful maintenance of the 
segregation between host and bacteria to avoid unnecessary immune responses and to guarantee 
homeostasis between the microbiota and the host (Belkaid and Hand, 2014). Th e gut microbiota 
is crucial for proper development of the immune system, for example the immune system must 
evolve adaptations that allow for the preservation of the benefi cial relationship but protect the 
host from e.g. pathogens by compartmentalizing the bacteria (Hooper et al., 2012). One such 
method is the mucus layer separating the microbiota from epithelial cells. It has been shown that 
both mice (Johansson et al., 2008) and humans (Johansson et al., 2014) possess a mucus barrier 
consisting of two layers. Th ese are the loosely adherent mucus layer closer to the lumen and the 
fi rmly adherent mucus layer protecting the epithelial cells. Th e inner mucus layer is impervious 
to microbes, preventing most of the contact between microbes and host. Th e inner mucus layer 
is constantly converted into the outer layer, which provides nutrients and attachment sites for 
several bacteria. Th e mucus layer acts as a physical barrier, together with tight junctions between 
the epithelial cells to prevent contact between intestinal microbiota and host cells. 
Th e co-existence of the microbiota and host starts to develop at birth. Th e infant gut was 
previously thought to be sterile, however there is evidence that the infant receives his/hers 
initial inoculum from the mother before birth, since commensals have been found from both 
placenta (Satokari et al., 2009) and the meconium (Moles et al., 2013). Nevertheless, most of the 
microbiota development occurs in the postnatal phase with a major contribution from maternal 
microbes (Belkaid and Hand, 2014). Th erefore it is thought that life events such as mode of 
delivery (Dominguez-Bello et al., 2010), feeding patterns and mothers’ specifi c microbiota 
composition have an eff ect on infants’ microbial signatures (Penders et al., 2006).  Th e maturation 
of microbiota continues when solids are introduced to the infant’s diet (Palmer et al., 2007) and 
gradually develops all the way to adolescents (Agans et al., 2011; Ringel-Kulka et al., 2013).
Th e composition and the amount of bacteria in the intestine of a healthy adult vary along 
the digestive tract (Figure 1). Th e vast majority of the intestinal bacteria reside in the colon, 
reaching values between 1012 to 1013 bacteria per gram of faeces. Th e composition of the diff erent 
locations of the intestinal tract varies due to diff erent environmental factors, such as pH, transit 
time, mucus layer and peristaltic movements. Although the GI tract microbiota predominantly 
contains bacteria (94%), there are also viruses (4.8%) and archaea (0.5%) (Arumugam et al., 
2011). 
2.2.1  CHARACTERISTICS OF HEALTHY ADULT INTESTINAL MICROBIOTA
In order to study the intestinal microbiota of healthy subjects, a defi nition of what constitutes 
intestinal health and how to measure it must be determined. Th e World Health Organization 
specifi ed in 1948, “Health is a state of complete physical, mental and social well-being and not 
merely the absence of disease or infi rmity”. When related to GI health, this defi nition could be 
refi ned to include several other aspects, such as the absence of GI complaints, normal digestion 
and absorption of foods, normal immune status, normal intestinal microbiota and a good quality 
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8of life (Bischoff , 2011). Th is multifaceted health status can be assessed with diagnostic measures 
covering both subjective perceptions of the GI health as well as objective parameters, both 
summarized in Table 3.
Table 3:  Assessment of the gastrointestinal health status.
Subjective parameters
Measure Method Description Reference
General health Health related quality of life -questionnaires Validation of the general health and well-being
Hays 1993,
Barry 2007
Psychological 
status
Hospital anxiety and 
depression score 
(HAD)
Widely used assessing depression and anxiety 
measures in healthy controls and patients Zigmond 1983
GI symptoms IBS severity scoring Assessing intestinal symptoms and their se-verity
Spiller 2010, 
Talley 1989 
Stool consistency Bristol stool scale
7-stage scale helps to diagnose subjects with 
constipation (type 1 and 2), normal stool (type 
3 and 4) and diarrhoea (type 5 to 7)
Lewis 1997
Diet Food frequency ques-tionnaires Evaluating the subjects’ habitual diet Riboli 2002
Objective parameters
Measure Method Description Reference
GI function Transit rate 
Hinton’s test based on ingestion of radioactive 
beads and the progress is monitored with 
X-rays
Hinton 1969
  Digestion Measuring nutrients such as fats or macronu-trients from the stool or blood
Khouri 1989 
Benzie 2014
Permeability
Evaluation of the integrity of intestinal barrier 
based on the movement of small indigestible 
particles from the intestine to urine
Teshima 2008
  Motility Measures of peristaltic movements, and gut wall tension
Whitehead 
1997 
  pH Stool pH refl ects the microbial production rate of organic acids Walker 2005
Immunity & 
Infl ammation Cytokine measures
Measurement of the infl ammatory cytokines 
(e.g. IL-6, IL-1 and TNF-a) or the anti-infl am-
matory cytokines (e.g. IL-10) or the expression 
of these genes as a means of evaluating infl am-
mation
Swan 2013
Epithelial integrity Visualisation of the epithelial layer e.g. with histological means
Martinez 
2012, Johans-
son 2014
  Calprotectin
Detection of neutrophilic protein, calprotectin, 
from faecal samples as an indication of intesti-
nal infl ammation
Roseth 1992
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9MICROBIAL COMPOSITION AND DIVERSITY
Th e bacterial composition, though demonstrating great variation from subject to subject, 
contains over 90% of Firmicutes and Bacteroidetes, additionally Actinobacteria, Proteobacteria, 
and Verrucomicrobia are among the most abundant phyla (Li et al., 2014; Qin et al., 2010). 
Healthy subjects are reported to harbour around 400-600 diff erent species in their colon (Qin 
et al., 2010; Rajilic-Stojanovic et al., 2007; Salonen et al., 2012; Tap et al., 2009). Th e bacteria 
reside in the lumen or become attached to the mucosal layer of the gut. Th e defi nition of health 
and healthy intestine does not take into account the vast natural variation and subject-specifi city 
of the intestinal microbiota. It has been shown that the relative abundance of both Firmicutes 
and Bacteroidetes can vary between 0 to 99% (Huttenhower et al., 2012) and the most abundant 
phylotypes can diff er by as much as 5000-fold between subjects (Huse et al., 2008). To date the 
intestinal microbiota of over 1500 healthy subjects has been characterized (Huttenhower et al., 
2012; Lahti et al., 2014; Qin et al., 2010) and no clear species collection specifi c for health has 
been identifi ed. Due to the vast individual variation in composition, a detailed catalogue of a 
healthy microbial composition is not feasible. However, there are several components that can be 
used to distinguish the healthy intestinal microbiota; these will be discussed in the next sections.
Th e diversity of the intestinal microbiota is an ecological measure of the community 
structure consisting of species richness, the amount of diff erent species, and species evenness, the 
relative abundance of those species. High diversity is thought to be benefi cial in an ecosystem, 
allowing it to cope better with stressful conditions. High diversity has been associated to low 
temporal variation and was shown to be a subject-specifi c feature of the microbiota (Flores 
et al., 2014). Moreover, there are several reports indicating that decreased diversity can be 
associated with disease conditions such as IBS (Noor et al., 2010), infl ammatory bowel disease 
(IBD) (Manichanh et al., 2006; Rajilic-Stojanovic et al., 2013) and obesity (Tap et al., 2009), 
also nutrition and alterations to the habitual diet are known to drastically aff ect the microbial 
diversity and composition (Salonen et al., 2014). Th e intestinal microbiota can rapidly adapt to 
the specifi c nutrient abundance, producing specifi c metabolites that generate diff erent metabolic 
responses in the host (David et al., 2014). Together this indicates that high diversity could be 
benefi cial to health and result to more stable microbiota. 
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SUBJECT SPECIFICITY
Each individual’s microbiota is most similar to their own samples (Costello et al., 2009; 
Turnbaugh et al., 2009; Zoetendal et al., 1998) followed by their close relatives and then by 
unrelated individuals (Tims et al., 2013). Th is high subject-specifi city has been shown to be a 
combination of environmental factors shaping the microbiota immediately aft er birth as well due 
to genetic variation (Benson et al., 2010; Kashyap et al., 2013b; Wacklin et al., 2011). It appears 
that the functions performed by the microbiota and its composition do correlate with each other, 
indicating that there is redundancy in the functional properties of the intestinal microbiota that 
allow the observed individuality but retain the important functions (Huttenhower et al., 2012; 
Muegge et al., 2011). It has been shown that the minimal set of functions contains pathways 
necessary for bacterial homeostasis as well as gut specifi c pathways such as adhesions to the host 
proteins and harvesting energy in the gut environment (Qin et al., 2010). 
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Figure 1: Characteristics of the adult intestinal tract and microbiota (Lozupone et al., 2013; 
Walker and Lawley, 2013; Zoetendal et al., 2012) 
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TEMPORAL STABILITY AND RESILIENCE 
From the ecological point of view, resilience represents a community’s ability to respond to 
perturbations by resisting change and the ability to recover to its original form (Holling, 1973). 
Th e capability for the microbiota of healthy subjects to maintain its composition in time has 
been associated to health in several studies. It has been shown that the microbiota retains its 
similarity over time, both the short and long term (Delgado et al., 2006; Krogius-Kurikka et al., 
2009; Martinez et al., 2013; Maukonen et al., 2006; Scanlan et al., 2006; Tannock et al., 2000; 
Vanhoutte et al., 2004; Yatsunenko et al., 2012; Zoetendal et al., 1998). It is also known that there 
is little fl ux in the presence of the species but their abundances vary in time (Rajilic-Stojanovic et 
al., 2012) and that the temporal variation was associated to subjects’ microbial diversity (Flores 
et al., 2014). Th e majority of the current data supports the view that the intestinal microbiota of 
a healthy adult operates in a state of homeostasis and shows resilience to perturbations such as 
lifestyle changes, medication and diet. 
CORE MICROBIOTA
Regardless of the high individuality, if the hallmarks of a healthy intestinal microbiota are 
temporal stability, high diversity and conserved key functions, it would be plausible to think 
that at least to a certain degree there would be similarities in the microbiota composition 
among healthy individuals. In a large European cohort, all healthy adults were found to harbour 
approximately 160 high-abundance species, several of these were shared between individuals, 
although in highly variable abundances (Qin et al., 2010). It would be tempting to assume that 
species detected in the majority of healthy subjects would have been conserved throughout 
evolution and would be benefi cial for health. Th ere are several studies showing that this kind of 
common microbial core can be detected in healthy individuals (Claesson et al., 2010; Martinez et 
al., 2013; Qin et al., 2010; Rajilic-Stojanovic et al., 2009; Salonen et al., 2012; Sekelja et al., 2011; 
Tap et al., 2009; Turnbaugh et al., 2009; Turnbaugh et al., 2007; Willing et al., 2010). Th e largest 
studies have estimated that the core microbiome contains approximately 30% of the detected 
phylotypes consisting mainly of Firmicutes (Ruminococcus, Eubacterium and Faecalibacterium 
spp.), Bacteroides spp. and Actinobacteria (Bifi dobacterium ssp.) (Qin et al., 2010; Salonen et al., 
2012). 
Another, more holistic approach for identifying conserved microbiota and similarities among 
healthy individuals was introduced by Arumugam and colleagues who revealed the existence of 
enterotypes (Arumugam et al., 2011). Th ey hypothesised that the intestinal microbiota of healthy 
adults could be divided into three high-level ecosystem solutions based on the abundance of the 
so-called driver species. Th ese included Bacteroides (Enterotype 1), Prevotella (Enterotype 2) or 
Ruminococcus (Enterotype 3). Th ey have been shown to remain relatively stable over a period of 
at least 6 months (Roager et al., 2014) and there is evidence of fl uctuations between enterotypes; 
these were revealed in a 10-year follow-up study (Rajilic-Stojanovic et al., 2012). Moreover the 
enterotypes appeared to be independent of gender and nationality, however long term dietary 
habits are known to be associated with enterotypes 1 and 2 (Wu et al., 2011). 
2.3  EFFECTS OF PERTURBATION TO HEALTHY INTESTINAL MICROBIOTA
Th ere is overwhelming evidence that changes to the intestinal microbiota can be associated with 
a variety of disease states (detailed in Table 4). In addition, perturbations such as consumption of 
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antibiotics are known to alter the intestinal microbiota of healthy individuals (Dethlefsen et al., 
2008; Jernberg et al., 2007; Vrieze et al., 2013). Th e phylotypes aff ected by an antibiotic treatment 
tend to be subject-specifi c, but there is evidence that some phylotypes, such as members from 
the Bacteroidetes phylum, do not recover even several months aft er the treatment, and a long-
term reduction in the diversity has also been observed (Dethlefsen and Relman, 2011; Jakobsson 
et al., 2010). It has been hypothesized that the increased use of antibiotics might have altered 
the microbial composition of Western people, and associations between obesity and use of 
antibiotics are emerging (Th uny et al., 2010).
Th is thesis concentrated on the evaluation of two diff erent perturbations; the eff ect of bowel 
cleansing of the healthy intestine and the characterisation of the intestinal microbiota of IBS 
patients. Th e current literature of both cases will be discussed next. 
Table 4: Disease states with associations to altered intestinal microbiota.
GASTROINTESTINAL DISORDERS
Disease Primary fi ndings References
Celiac disease
Increased amounts of Firmicutes and Proteobacteria such as 
Sutterella wadsworthensis and lower proportions of Actinobac-
teria detected in children with risk for genetic predisposition for 
the disease
Cheng  2013, 
Olivares  2014
Clostrium diffi  cile 
infection
Decreased diversity, faecal material transplant from healthy 
individual cures patients
Fuentes  2014, 
van Nood  2013
Colorectal cancer Reduced amounts of SCFA-producing Firmicutes, low-grade in-fl ammation induced by the microbiota, increased Fusobacteria
Kostic  2012, 
Plottel 2011, 
Zhu 2013
Crohn’s disease
Reduced diversity, temporal instability, decreased amount of 
Firmicutes such as Faecalibacterium prausntizii and increased 
amounts of Proteobacteria
Loh 2012, 
Manichanh 2006, Sokol 
2008
Necrotizing en-
terocolitis
Increased immune reaction in preterm infants induced by 
members of Enterobacteriaceae family Wang  2009
Ulcerative colitis Reduced diversity, decreased levels of Firmicutes and Akkermansia muciniphila
Lepage  2011,
Loh 2012
Rajilic-Stojanovic 2013
SYSTEMIC DISORDERS
Disease Findings References
Arthritis  Increased levels of Proteobacteria and Bacteroidetes Taneja, 2014
Autism
Increased levels of Lachnospiraecae spp. Ingestion of Bacteroides 
fragilis reduced symptoms in mice. Increased levels of Sutterella 
spp . and Ruminococcus torques in humans
Hsiao  2013, 
Wang  2013, 
Depression Oscillibacter and Alistipes increased in patients, probiotics  seem to alleviate symptoms
Naseribafrouei  2014, 
Dinan  2013
Metabolic syn-
drome and type 2 
diabetes
Lower diversity, lower level of SCFA-producing Firmicutes. 
Insulin sensitivity improved aft er faecal microbiota transplant 
Karlsson 2013, 
Vrieze 2013 
Obesity
Inconclusive results regarding the Firmicutes/Bacteroidetes 
ratio. Increased capacity for energy harvest and low-grade in-
fl ammation. 
Ley 2006b, 
Moreno-Indias  2014, 
Turnbaugh 2009, 
Qin 2010
Type 1 Diabetes Lower diversity, larger Bacteroidetes/Firmicutes ratio Kriegel  2011, Murri 2013
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2.3.1  EFFECT OF BOWEL CLEANSING TO THE INTESTINAL MICROBIOTA
Colonoscopy is an endoscopic procedure used for examining the large bowel and distal parts of 
the small bowel. It is intended for visual diagnosis of several gastroenterological diseases such 
as IBD, polyps and colon cancer. An essential preceding step for a successful colonoscopy is to 
remove all faecal particles and to reduce the bacterial load in the GI tract. Th is is achieved by 
administration of purgatives such as polyethylene glycol (PEG) supplemented with electrolytes. 
Consumption of osmotically active bowel cleansing agents increases the amount of water in 
the intestinal tract, washing out the luminal matter and reducing the colonic faecal material, 
including the intestinal bacteria, and introduces oxygen into the normally anaerobic colonic 
ecosystem (Strocchi et al., 1990). Moreover, the rapid increase in bowel movements will further 
fl ush out those bacteria incapable of adhering to the gut mucosa, distorting the microbiota 
composition compared to the normal state. All these rapid changes may aff ect the microbial 
ecosystem and impede its restoration.
 Although consumption of purgatives has been shown to be safe for the patient, there 
is little consensus about how the intestinal microbiota is aff ected by the procedure, especially 
regarding the potential long-term consequences. It has been reported that the intestinal 
microbial composition is altered momentarily aft er the consumption of purgatives (Gorkiewicz 
et al., 2013; Harrell et al., 2012; Mai et al., 2006; O’Brien et al., 2013), but the observed changes 
have been shown to be relatively subject-specifi c, with little agreement on which bacterial taxa 
are aff ected. Th e main reason for the inconclusive evidence is likely to be the small number 
of study subjects or the lack of analytical depth in the previous studies. Surprisingly, there are 
several reports indicating that lavage does not alter the microbial diversity even when the total 
bacterial load was halved (Gorkiewicz et al., 2013; Harrell et al., 2012; O’Brien et al., 2013). 
Moreover, there are indications that the bowel cleansing might cause temporary changes in the 
mucus layer (Johansson et al., 2014) and reports of the microbial changes in the mucosal tissue 
aft er bowel preparation have shown a trend towards increased amounts of pathobionts from the 
Proteobacteria phylum (Gorkiewicz et al., 2013; Harrell et al., 2012).  
2.3.2  DIFFERENCES IN THE INTESTINAL MICROBIOTA IN DISEASES  - IRRITABLE 
BOWEL SYNDROME
Irritable bowel syndrome is one of the most common gastrointestinal disorders in the Western 
world, aff ecting approximately 10-15% of the population (Spiller et al., 2007). Th is patient group 
is very heterogeneous and it is characterized by abdominal pain and discomfort. IBS has not been 
associated with the development of serious diseases or higher mortality rate, with the exception 
of increased suicidal behaviour in patients suff ering the chronic symptoms of abdominal pain 
(Spiegel et al., 2007). Th e patient groups can experience a variation of abnormal bowel habits 
and these are used to subdivide the patients into smaller groups of IBS with diarrhoea (IBS-D), 
IBS with constipation (IBS-C) and IBS with alternating bowel habits (IBS-A) (Longstreth et al., 
2006). Th e above-mentioned symptoms can be common even in healthy subjects, but the IBS 
patients experience these chronically, reducing their quality of life. Th e diagnosis is based on 
symptom evaluation and elimination of more serious, organic diseases. Th e patient evaluation 
can be based on several diff erent diagnostic criteria including the Manning (Manning et al., 
1978) and the most frequently used Rome criteria with three versions, Rome I (Drossman et al., 
1990) Rome II (Th ompson et al., 1999) and Rome III (Longstreth et al., 2006). All distinguish the 
IBS patients in approximately 75% of the cases, however only 50% of patients with IBS meet all 4 
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symptom-based diagnostic criteria, emphasizing the need for developing more accurate ways of 
diagnosing IBS (Ford et al., 2013). 
Th ere is no single unifying cause reported for IBS (Camilleri, 2012). Several indicative 
factors have been identifi ed, including genetic predisposition (Saito et al., 2010), prior episodes 
of anxiety and depression and female sex, which all have been shown to increase the risk of 
developing IBS (Koloski et al., 2012). Th e condition is heterogeneous in terms of its clinical 
presentation so it is tempting to hypothesize that there are several reasons for the underlying 
aetiology and pathophysiology. Moreover, there is strong evidence indicating that intestinal 
microbial composition could be one of the contributing factors in the aetiology of the disease. 
Th is is supported by the fact that the strongest predictor of onset of IBS is a prior gastroenteritic 
episode which will increase by 7-fold the risk for developing IBS (Rodriguez and Ruigomez, 
1999). 
MICROBIAL CHANGES IN IBS AND THEIR RELEVANCE TO THE SYMPTOM DEVELOPMENT
Th e microbial component in the aetiology of IBS has been studied extensively in the past 
decade and the development of molecular techiques in teh microbiota analysis have provided 
evidence for the involvement of microbiota in the pathogenesis of IBS. Several studies have 
reported diff erences in diversity, both increase (Saulnier et al., 2011) and decrease (Carroll et 
al., 2011), and temporal stability of the intestinal microbiota (Durban et al., 2013; Kajander et 
al., 2007; Kajander et al., 2008; Mättö et al., 2005). Most of the studies (summarized in Table 5) 
show changes in the intestinal microbiota composition between the IBS patients and the healthy 
controls. However, the reported changes are inconclusive or even contradictory and show little 
overlap from study to study. Th is is likely due to both lack of standard operation procedures in 
the data collection and analysis of the intestinal microbiota as well as in the patient recruitment. 
Th e observed diff erences may derive from heterogeneous patient material due to diffi  culties 
in the diagnosis of IBS patients, the high individuality of the faecal microbiota, and therefore 
inadequate sample sizes. Regardless of the lack of coherent changes in the compositional 
analysis, the evidence for the role of microbiota in the pathogenesis of IBS is supported by the 
following arguments. Firstly, the IBS symptoms can be improved with several diff erent agents 
targeting the intestinal microbiota, including some probiotics and prebiotics (Whelan, 2011) as 
well as antibiotics such as rifaximin (Menees et al., 2012). Secondly, though there is a lack of 
clear microbial signature, the microbial composition of the IBS patients is shown to be diff erent 
from that of the healthy controls (detailed in Table 5). Th irdly, about 10% of the IBS cases are 
reported to have began aft er an episode of gastroenteritis, causing post-infectious IBS (PI-IBS), 
indicating a cause and eff ect relationship (Chaudhary and Truelove, 1962; Spiller and Garsed, 
2009). Several diff erent pathogens causing the gastroenteritis prior the onset of PI-IBS have been 
identifi ed, including Camplylobacter jejuni (Spiller et al., 2000), Escherichia coli (Okhuysen et 
al., 2004) and Salmonella (Mearin et al., 2005). In addition, there are studies showing a potential 
genetic predisposition for development of the PI-IBS, showing alterations in genes encoding for 
proteins involved in epithelial cell barrier function and the innate immune response to enteric 
bacteria (Swan et al., 2013; Villani et al., 2010). 
Th e presence of low-grade infl ammation or immune activation is well documented in IBS 
patients but the cause is not known (Chadwick et al., 2002; Spiller, 2004). Furthermore, it has 
been speculated that the altered microbial composition could be a driver for these changes. IBS 
patients with alternating bowel symptoms (IBS-A) have been demonstrated to have increased 
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expression of Toll-Like Receptors (TLRs) (Belmonte et al., 2012; Brint et al., 2011). TLRs are 
structures recognising e.g. the outer cell wall structures of the intestinal microbiota and other 
structurally conserved regions of bacteria, highlighting the potential of the microbiota in the 
development of low-grade infl ammation. In other studies, mast cells and lymphocytes have been 
associated with the symptom development, although the reasons for their increased numbers are 
not fully understood (Spiller et al., 2000). Th ere have been speculations about the role of intestinal 
microbiota, since rats with a dysbiosis due to antibiotic treatment display increased levels of 
mast cells (Nutten et al., 2007). Moreover, the altered intestinal microbiota has been associated 
with host immune markers, including the increased numbers of mast cells in the patients (Study 
IV). Furthermore, the increased expression of TLR2 and TLR4 have been associated with IBS 
subtypes providing further support for the hypothesis that there is altered intestinal immune 
activation and a role for intestinal microbiota in the aetiology of IBS (Belmonte et al., 2012).
Closely related to the development of low-grade infl ammation is the maintenance of the 
mucosal barrier separating the microbial content from the intestinal epithelium. Th e integrity 
of the epithelial cell barrier has been linked to the development of IBS where the tight junction 
proteins, such as ZO-1, were shown to have decreased expression and this phenomena has 
also been demonstrated in intestinal tissue cross sections (Martinez et al., 2012). Although the 
microbial composition of these subjects was not determined, if there was leaky epithelium there 
would be an outfl ow of antigens causing stimulation of the mucosal immune system and low-
grade infl ammation, irrespective of the actual microbial composition. 
Th e altered abundance of methanogenic archaea has been associated with both IBS-D and 
IBS-C subtypes. Organisms in this group recycles intestinal hydrogen into methane and the 
levels of this organic material have been shown to be increased in the constipation predominant 
patients (Menees et al., 2012; Chatterjee et al., 2007; Furnari et al., 2012; Pimentel et al., 2003) 
and reduced in the diarrhoea-predominant patients (Study IV; Rajilic-Stojanovic et al., 2011). 
Methane is known to slow down the intestinal transit and the levels of methane excretion have 
been positively associated with constipation in IBS patients. Th is suggests that the methanogens 
might play a role in the symptom development in the IBS-C patients. However, since the 
organisms grow slowly and are sensitive to increased transit time (Pimentel et al., 2006) their role 
in constipation might be secondary rather than causative.
One of the most consistently IBS associated bacterial phylotypes is an uncultured relative of 
Ruminococcus torques (Kassinen et al., 2007). Th is species has been shown to be more abundant 
in several IBS cohorts in comparison to controls (Kassinen et al., 2007; Lyra et al., 2010; Rajilic-
Stojanovic et al., 2011; Saulnier et al., 2011). Th is, still uncultured, phylotype has been associated 
with an increased sensation of pain (Malinen et al., 2010) and its numbers were reduced when IBS 
patients received probiotic supplements (Lyra et al., 2010). Th e closest relative of this phylotype 
(Lachnospiraceae bacterium A4) is known to possess the pro-infl ammatory fl agellin proteins, 
which has been associated with IBS (Schoepfer et al., 2008). Th is bacteria has the capability to 
degrade mucus (Hoskins et al., 1985) and its abundance is believed to be increased in Crohn’s 
disease (Prindiville et al., 2004) and Ulcerative colitis (Png et al., 2010). 
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Table 5: Summary of studies characterising the intestinal microbiota in IBS patients.
Microbial result (IBS vs. HC) Study size (IBS/HC)
Diagnostic 
criteria
Sample 
source Method Reference
IBS patients clustered to both 
IBS-like microbiota and HC-
like microbiota
Increased: Firmicutes (Dor-
ea,Blautia), Actinobacteria 
(Bidifobacteria) 
Decreased: Bacteroidetes
 37/20
Rome II 
(D=15, C=10, 
A=12)
F
Pyrosequencing 
(16S rRNA V4) 
~30000 reads/subect 
Jeff ery 2012
Increased:
Enterobacteriaceae, Fusobac-
terium, Pseudomonadaceae, 
Lactobacillaceae 
Decreased: stability, richness, 
Faecalibacterium 
 23/23 Rome III (D=23) F
qPCR, Pyrosequen-
sing (16S rRNA 
V1-3 and V6) ~7400 
reads/subject 
Carroll 2012
Smaller core microbiota in IBS 
children,
Increased: 
β- and δ-Proteobacteria, Me-
gasphera, Parasporobacterium,
B. thetaiotaomicron, 
B. ovatus, 
Decreased: Dehalobacter, 
Fusobacter, Oxobacter, Bifi do-
bacterium
 22/22 Rome II (D=22) F
Phylogenetic mi-
croarray, qPCR, 
FISH
Rigsbee 2012
General eff ects in IBS 
Increased: Papillibacter, rela-
tives of C. orbiscindens, Blau-
tia, Peptococcus, C. diffi  cile, C. 
nexile ,C. symbiosum, C. eu-
tactus, Lachnospira, R. gnavus 
and Dorea 
Decreased: bifi dobacteria, 
Bacteroidetes, Uncultured 
Clostridiales     
62/46
Rome II 
(D=22, C=18, 
A=19)
F Phylogenetic mi-croarray
Rajilic-
Stojanovic 
2011
Increased: Diversity, 
δ-Proteobateria, Dorea, Veil-
lonella, Bacteroides, Anaer-
ovorax, Ruminocuccus-like 
phylotype
Decreased: Eubacterium, 
Bacteroides
 22/22
Rome III 
(D=1,C=13, 
U=8)
F
Phylogenetic 
microarray, 
Pyrosequensing 
(16S rRNA V1-V3 
and V3-V5) 
~54200 reads/subject
Saulnier 2011
Increased: Staphylococcus 
aureus  96/23
Rome I and II 
(D or A=81, 
C=15)
F qPCR Rinttilä 2011
Increased:
 Pseudomonas aeruginosa  37/20
Rome II 
(D=13, C=11,  
A=13)
F, M DGGE, qPCR Kerckhoff s 2011
Decreased: Diversity (F)  16/21 Rome III (D=16) F, M T-RLFP Carroll  2011
Increased: Diversity, total 
bacterial load, Bacteroidetes, 
Lactobacillus  
Decreased: Clostridium coc-
coides et rel., Bifi dobacterium 
 11/8 Rome II (U=8) F qPCR, DGGE 
Ponnusamy  
2011
Increased: Lactobacillus, Veil-
lonella  26/26
Rome II 
(C=11, D=8, 
A=7)
F qPCR, culturing Tana 2010
Increased: Bacteroides 
Decreased: Diversity  11/22
Rome II 
(U=11) F DGGE Noor 2010
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Microbial result (IBS vs. HC) Study size (IBS/HC)
Diagnostic 
criteria
Sample 
source Method Reference
Increased: aerobic bacteria, 
Lactobacillus (F)  10/10   F, M culturing, qPCR Carroll  2010
Increased; Proteobacteria, 
Lachnospiraceae
Decreased: Actinobacteria, 
Bacteroidetes
 10/22 Rome II (D=10) F
%G+C, sanger 
sequensing, qPCR
Krogius-
Kurikka 2009
Increased: R. torques 94%  
Decreased: C. aerofaciens, C. 
eutactus 97%, C. cocleatum 
88%,  B. catenulatum
24/23
Rome II 
(D=10, C=8, 
M=6)
F %G+C, sanger sequensing, qPCR
Kassinen 
2007
D = diarrhoea-predominant IBS
C = constipation-predominant IBS
A = alternating-type IBS
U= unclassifi ed
F = Faecal sample
M = mucosal sample
Review of the Literature
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3.  AIMS OF THE STUDY   
Th e general aim of the thesis was to characterise the intestinal microbiota of healthy subjects 
and to benchmark it to conditions with expected microbiota aberrations due to PI-IBS or bowel 
cleansing.  Th e microbial profi les were correlated to several clinical measurements to identify 
interrelations between the microbiota and host health.  Th e specifi c aims of the studies were:
I)  Comparison of the effi  cacy of widely used faecal DNA extraction methods and the 
determination of the biases that they introduce to the microbial community in order to 
select the optimal method to be used in subsequent studies.
II)  Characterization of the normal healthy adult microbiota and determination of the 
extent of temporal changes as well as determining the composition and stability of the 
microbiota shared by these individuals (the core microbiota).  
III)  Determination of the eff ects of bowel cleansing procedure on the healthy intestinal 
microbiota and the eff ects of diff erent doses of the purgative agent.
IV)  Comparison of the microbiota composition between healthy individuals and post-
infectious irritable bowel syndrome patients with an attempt to facilitate the future use 
of microbiota for stratifi cation of the patient material
Aims of the Study
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4.  MATERIALS AND METHODS
4.1  STUDY SUBJECTS
All subjects taking part in the four studies provided written informed consent. Th e samples used 
in the studies I and II were part of a clinical trial (Kekkonen et al., 2008) and the ethics committee 
of the Hospital District of Helsinki and Uusimaa approved the study protocols. Th e Nottingham 
Research Ethics Committee approved studies III and IV, the latter was a subset of a larger clinical 
trial (Swan et al., 2013). A summary of the study subjects is provided in Table 6.
Unpublished data on intestinal symptoms of healthy subjects were collected from 46 Finnish 
adults taking part in a science outreach “Tiedekulma”, organized in 2012. 
Table 6: Th e study subjects.
Study Number of subjects Clinical status Sex (f/m) Mean age (range)
I 5 + 19 Healthy 2/3 + 14/5    42 (34-54) + 42 (25-56)
II 15 Healthy *  10/5 42 (28-56)
III 23 Healthy  12/11 26 (19 - 50)
IV 57
IBS-D: 12,
PI-IBS: 11,
PI-BDa: 11,
PI-nonBDb: 12,
Healthy: 11
36/21 42 (20 - 68)
Th esis 54 Healthy 34/20 34 (25 - 62)
* During the trial, divided into subgroups: 5 compromised and 9 healthy, see study II Table 1
a  PI-BD = post C. jejuni infection bowel dysfunction
b PI-nonBD = post C. jejuni infection with out bowel dysfunction
4.2  ANALYSIS PROTOCOL 
All of the studies followed a similar analysis pipeline, starting from faecal DNA extraction with 
the DNA extraction method validated in the Study I, combining the mechanical lysis by repeated 
bead beating to chemical lysis of cells, and purifi cation of DNA with the QIAamp DNA Mini Kit. 
Th e resulting DNA was amplifi ed with universal primers targeting the hypervariable V1 and V6 
regions of 16S rRNA gene (Rajilic-Stojanovic et al., 2009).  Th e PCR product was transcribed into 
RNA, labelled with Cy3 or Cy5 followed by fragmentation and hybridization on the microarray. 
Aft er scanning the arrays, the raw data was normalized not only to reduce outliers and technical 
biases within the samples but also to normalize the signals between the arrays. Th e phylogenetic 
microarray analysis was complemented with qPCR analysis (detailed in Table 7).
Th e bioinformatic analysis of the samples utilised the analytical methods summarized in 
Table 7, concentrating on fi nding diff erences in the microbial community between treatments or 
patient groups, or fi nding similarities between the microbiota of healthy subjects. Th e microarray 
and qPCR data were also correlated with diff erent host parameters in order to evaluate their 
co-variance (studies II, III, IV).
Materials and Methods
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Table 7: Methods used in the thesis.
  Method Study Reference
Sample preparation Faecal DNA extraction I, II, III, IV Study I
  DNA quantifi cation I, II, III, IV  
HITChip sample-wise 
normalization methods
Quantile between sample normal-
ization I, IV Bolstad  2003
 
Assumption of normal-exponen-
tial (background-signal) distribu-
tion and quantile normalization 
II Bolstad  2003
  Robust Probabilistic Averaging III Lahti  2011
Quantitative PCR from 
microbiota
Methanogenic archaea (Methano-
brevibacter spp.) I, II, III, IV Ufnar  2006
Total bacteria I, II, III Nadkarni  2002
  Clostridium coccoides-Eubacteri-um rectale -group I Rinttila  2004 
Bacteroides-Prevotella-Porphyro-
monas I, IV Rinttila  2004
  Bifi dobacterium genus I, II Rinttila  2004
Faecalibacterium prausnitzii II, III Rinttila  2004
  Ruminococcus torques -like phylo-type (94% similarity) IV Kassinen  2007
  Collinsella aerofaciens -like taxa IV Kassinen  2007
Statistical analysis Linear models (ANOVA, t-test, Wilcoxon) I, II, III, IV
Faraway 2002, 
Myles 1973 
Linear mixed models I, II, III, IV
Materials and Methods
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  Method Study Reference
 Statistical analysis
p-value correction for multiple 
testing (Tukeys Honest signifi cant 
diff erences, q-value estimation or 
Benjamini-Hochberg false discov-
ery rate )
II, III, IV, 
Benjamini 
1995,
Miller 1981,
Storey 2002
Correlations between data sets 
(Spearman or Pearson) II, III, IV
  Hierarchical clustering I, II, III  
Principal component analysis I Venables and Ripley, 2002
  Coeffi  cient of variation II  
Species enrichment with Fisher’s 
exact test II Rivals  2007
  Redundancy analysis III  
Gene set analysis IV
Efron 2007,
Subramanian 
2005
Bootstrap  aggregated redundancy 
analysis IV Study IV
Other analysed data Clinical data and laboratory test of patients III, IV  
  Quantitative PCR from the host I, III, IV Swan  2013
Questionnaires regarding GI 
symptoms
II, III, IV, science 
outreach (un-
published)
Hays  1993, 
Melzack, 1975, 
Spiller  2010, 
Study II
  Questionnaires regarding mental status III, IV
Zigmond and 
Snaith, 1983
Materials and Methods
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5.  RESULTS AND DISCUSSION
5.1  COMPARISON OF FAECAL DNA EXTRACTION METHODS (STUDY I)
When working with DNA-based molecular methods using complex study material, such as 
faeces, it is essential to use an unbiased DNA extraction method. Although the recovery of 
bacterial DNA from a faecal sample is a crucial step in obtaining a representative view of the 
intestinal microbiota, there is currently no consensus about what represents a standard operating 
procedure. Th e aim of this work was to examine the eff ects of diff erent faecal DNA extraction 
protocols on the composition and diversity of the recovered microbial DNA. Th e goal was to 
validate a standard DNA extraction protocol, which could be used in the subsequent studies. 
Th e evaluated DNA extraction methods represented diff erent principles for cell lysis and 
DNA purifi cation. Th e fi rst technique enriched the bacteria from faecal solids by diff erential 
centrifugation, followed by enzymatic, chemical and physical cell lysis, hereaft er referred as to 
the Diff erential Centrifugation and Lysis method (DCL, Apajalahti et al., 1998). Th e second 
method was a modifi ed version of the Promega Genomic Wizard DNA Purifi cation kit (MPR), 
relying primarily on enzymatic cell lysis (Ahlroos and Tynkkynen, 2009). Th e third method, 
subsequently referred to as repeated bead-beating (RBB), was initially develop for extracting 
DNA from bovine ruminal and faecal samples, which we optimised for human samples. Th is 
method employs physical disruption of bacteria, followed by purifi cation of DNA fi rst by 
precipitation and then through a column (Yu and Morrison, 2004). Th e fourth method was 
based on the commercial QIAamp® DNA Stool Mini Kit (QSK) preceded with brief mechanical 
cell lysis (Zoetendal et al., 2006). 
5.1.1  DIFFERENCES IN THE MICROBIOTA PROFILES BETWEEN THE DNA 
EXTRACTION METHODS
Th e effi  ciency of the DNA extraction protocols can be compared by assessing the quantity and 
quality of the extracts. We quantifi ed the amounts of total bacteria and methanogenic archaea 
with qPCR and found up 35-fold diff erences in the same sample, depending on the method. 
In general, the MPR yielded the highest amount of bacterial DNA and the QSK the lowest. 
In addition, there were statistically signifi cant diff erences in the amount of archaeal DNA. 
Again the QSK detected the lowest amounts of 16S rRNA copies, whereas the DLC and RBB 
methods yielded over 20-fold more archaeal DNA than the QSK method (p<.05). Moreover, 
we documented higher archaeal prevalence when applying mechanical lysis, indicating that the 
effi  ciency of DNA extraction method aff ects the detection limit for hard-to-lyse organisms. 
To further clarify the potential sources of the diff erences in the bacterial community structure 
attributing to the DNA extraction protocols, we analysed the samples with a phylogenetic 
microarray and the results were confi rmed by qPCR analysis targeting specifi c bacterial 
groups. Th e individuality of subject’s microbiota contributed most to the variation between the 
samples, as all methods and their technical replicates clustered by individual. When comparing 
the microbial profi les within a sample it was evident that the microbial profi le extracted with 
the QSK method diff ered the most from those extracted with the other methods (Figure 2). 
Th e compositional analysis of the diff erent extracts showed that all methods recovered all the 
predominant bacterial taxa, although the QSK-extracted DNA was enriched with Bacteroidetes 
in contrast to the other methods that retrieved relatively more Firmicutes. Additionally, the QSK 
method extracted less Actinobacteria as compared to the other DNA extraction protocols. A 
Results and Discussion
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recent study supported our results and indicated that the detected microbial composition was 
aff ected by DNA extraction, especially with the use of mechanical lysis. Similar to the present 
study, in the samples that were not subjected to extensive bead beating, various Gram-positive 
bacteria, especially bifi dobacteria and Blautia were severely underrepresented (Santiago et al., 
2014a). Th ese results confi rm and extend the earlier observations from Zoetendal and colleagues 
that increasing the bead beating time will result in the appearance of new Gram-positive bacterial 
species (Zoetendal et al., 1998).
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Figure 2: Comparison of the microbial profi les obtained from two subjects with four DNA 
extraction methods.  A) Hierarchical clustering visualizing the similarity of the phylogenetic 
fi ngerprints. a) and b) depict technical replicates. Th e abundance of B) Actinobacteria and 
C) Bacteroidetes phylum, as measured with microarray signal intensities. 
Th e observed diff erences in the microbial composition are likely to be explained by the 
ineffi  cient cell wall breaking capabilities in those methods lacking the mechanical lysis step. 
Gram-negative bacteria lyse more easily due to their thinner cell wall and hence these species 
become overrepresented in the mixed community if the more recalcitrant Gram-positive bacteria 
are not lysed by the applied extraction procedure. Th is highlights the importance of employing 
mechanical cell lysis in order to obtain a representative sample of the intestinal microbiota. 
However, another factor to consider is the conditions at cell lysis since when DNA degradation is 
not prevented rapidly lysing cells liberate DNA, which will be rapidly degraded. 
 Due to the above-mentioned biases introduced by the diff erent DNA extraction 
protocols, studies with dissimilar DNA extraction methods are not well comparable. In a recent 
meta-analysis microbiota samples tended to cluster together study-wise rather than according to 
the ethnicity or health status suggesting that there are technical biases in the results of diff erent 
studies (Lozupone et al., 2013). Although the DNA extraction procedure is only one of several 
potential sources of biases, it has been shown here and by others that it can infl uence the results 
profoundly (Claassen et al., 2013; Kennedy et al., 2014). However, further large-scale studies 
comparing the most commonly used extraction methods in suffi  ciently sized cohorts need to 
be conducted in order to achieve standard operating procedures for faecal DNA extraction 
methodology. Th is would allow better comparison of the data across diff erent studies and yield 
better quality results. 
 In conclusion, we have compared four conceptually diff erent faecal DNA extraction 
methods of which two, RBB and MPR, performed highly reproducibly and achieved a good 
representation of the intestinal microbiota, as refl ected in high DNA yield, high diversity and a 
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ratio of hard-to-lyse Gram-negative bacteria and archaea, and microbial composition comparable 
to that described in the literature (Qin et al., 2010, Turnbaugh et al., 2009). Th e major diff erence 
between these two extraction methods was the higher microbial diversity of RBB extracts 
and superiority in extracting the methanogens, meaning that the RBB was the optimal DNA 
extraction method for the following studies. 
Study I was one of the pioneering studies in validation of diff erent faecal DNA extraction 
protocols based on untargeted, community-wide microbiota analysis. Since the publication 
of our study, eff orts with larger cohorts and further methods have been made, taking steps 
towards the standardisation of DNA extraction protocols. Th e European Union-funded project 
International Human Microbiome Standards (IHMS) is aiming to for this. In this international 
collaboration, aliquots of pooled faecal samples were extracted with diff erent DNA extraction 
protocols (including the RBB methods described in Study I) and the extracted DNA was 
subsequently analysed by metagenomic sequencing analysis. Th e RBB method was found to 
meet the all quality criteria specifi ed in the fi rst IHMS progress report (IHMS, 2012) and was 
ranked among the top three of the DNA extraction protocols tested within the project (Joel Dore 
and Anne Salonen, personal communication).
5.2  CHARACTERIZATION OF THE HEALTHY MICROBIOTA (STUDY II)
Despite the overwhelming accumulation of data of the intestinal microbiota, a defi nition of 
the healthy microbiota is still lacking. Th e aim of Study II was to expand current knowledge by 
characterising the normal temporal variation of the healthy adult microbiota, its composition, 
diversity and stability as well as the common core microbiota, shared among most or all studied 
individuals. In addition, our objective was to identify potential associations between common 
and mild intestinal complaints and the microbial composition. To achieve this, we studied the 
intestinal microbiota of 15 Finnish adults, by collecting six faecal samples over a 7-week time 
period. Th e subjects evaluated their health status with a Health Related Quality of Life (HRQoL)-
questionnaire completed at the time of each faecal sampling. Th e participants were divided into 
groups of healthy (n=9) and compromised (n=6) subjects based on the results of the HRQoL-
questionnaire. Subjects without signifi cant deviations from Finnish reference values (Aalto, 
1999) and any self-reported life style changes that might eff ect the microbial composition were 
considered healthy. Th e compromised group consisted of subjects who reported signifi cant 
complaints of GI symptoms (n=2), antibiotic use (n=1), or who had travelled outside Finland 
(n=3).
5.2.1  HEALTHY MICROBIOTA COMPOSITION AND TEMPORAL VARIATION
Th e compositional analysis of the participants’ microbiota detected in all healthy subjects studied 
in this thesis (193 samples from 54 subjects) revealed on average 410 species-level bacterial 
phylotypes per sample. Th e most abundant phyla were Firmicutes (80%) followed by Bacteroidetes 
(10%) and Actinobacteria (1.5%). Members of the Proteobacteria and Verrucomicrobiota 
represented less than 1% of the total community. However, there was great diff erences between 
the subjects, as can be seen from Figure 3A; for example the relative abundance of Bacteroidetes 
varied from less than 1% to over 75% between the healthy individuals. Th e phylogenetic 
microbiota composition detected in these subjects was similar to that of healthy adults reported 
in previous publications (Qin et al., 2010) as well as studies appearing aft erwards (Huttenhower 
25
et al., 2012; Schnorr et al., 2014; Yatsunenko et al., 2012). When examining all of the healthy 
subjects of this thesis, the diversity showed large variation among participants. Moreover, when 
compared to the IBS patients there was a signifi cant decline (p<.05) in the Shannon diversity 
index as compared to all of the healthy controls evaluated here (Figure 3B).
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Figure 3: Microbial composition of healthy subjects. A) Composition of the healthy 
subjects studied in the four sub-studies of the thesis (N=193 from 54 subjects) ordered by 
the relative abundance of Bacteroidetes. B) Diversity of all healthy subjects  (N=54) studied 
in the thesis compared with the IBS patients (N= 24) from the Study IV.
Study II was set up to follow the temporal variation of the intestinal microbiota, which 
showed only a slight and non-signifi cant decline within the seven-week study period. Th is 
indicated that the healthy subjects’ microbiota was intrinsically stable, a view that has been 
supported also in later studies (Stein et al., 2013). A novel fi nding was that the taxa remaining 
most stable within an individual varied from person to person. In other words, the same 
bacterial group (e.g. bacteria related to Faecalibacterium prausnitzii.) could be one of the most 
variable in one individual and among of the most stable in another, highlighting the fact that 
there is subject-specifi city in the microbial composition as well as stability of microbes in 
healthy subjects. However, some common trends in the temporal dynamics of the intestinal 
bacteria could be observed. Th e temporal variation of individual taxa (measured as Coeffi  cient of 
Variation, CoV) was on average 6.3% and the same measured over the whole microbiota profi le 
was 4%, indicating that the healthy subjects microbiota had high temporal stability. Nonetheless, 
phylotypes related to the Bacteroides vulgatus and uncultured Clostridiales were some the least 
stable taxa (CoV 10.0% and 13.3% respectively) in most of the subjects whereas phylotypes 
related to Clostridium symbiosum and Ruminococcus obeum remained stable over the 7-week 
study period in most of the participants (average CoV 4.4% and 3.7%, respectively). Th e observed 
high temporal stability indicates that there is host-specifi c selection of the intestinal microbial 
composition and is evidence for an individual core microbiota. One of the characteristics of a 
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healthy intestinal microbiota has been suggested to be the ability to be resilient to change and 
to maintain its composition and more importantly, the function of the microbiota (Lozupone et 
al., 2012). Th ere has been several studies supporting our fi ndings of temporally stable microbiota 
with both short- (Scanlan et al., 2006; Vanhoutte et al., 2004) and long-term follow-up (Rajilic-
Stojanovic et al., 2012). Th e ability to understand the temporal stability maintained by the 
microbiota would represent an important step in being able to predict diseases that resulted in 
alterations in the microbial community and for the long term in the development of therapies to 
retain the balance. 
5.2.2  DEFINITION OF THE COMMON CORE MICROBIOTA
One way of defi ning the healthy microbiota is to concentrate on the commonly shared bacteria, 
conserved through the co-evolution of the host and intestinal inhabitants. It would be plausible 
to hypothesize that the composition of the common core microbiota would have been selected 
to include bacterial taxa with health-associated properties. Th erefore, once characterized, they 
could possess diagnostic and therapeutic potential. 
Previously the common core microbiota has been determined with somewhat arbitrary pre-
defi ned criteria for the prevalence of the detected phylotypes, i.e. a phylotype was required to be 
detected in a certain percentage of study subjects, ranging from 50% (Tap et al., 2009) to 100% 
(Qin et al., 2010) of the subjects. In the absence of established prevalence thresholds, it is diffi  cult 
to compare studies examining the common core. In addition, in these studies the number of 
study subjects varied and their health status had not been determined. Moreover, the results may 
well have been aff ected by methodological issues including coverage of the selected primers, and 
the choice of hypervariable regions of the 16S rRNA gene (Turnbaugh et al., 2009) as well as the 
analysis depth (Hamady and Knight, 2009) and the phylogenetic assignment (Claesson et al., 
2009).
Th e approach followed in Study II was to consider the common microbial core as an 
outcome of continuous prevalence and detection thresholds, i.e. to refrain from using pre-set 
thresholds since it was unclear which of these thresholds would be biologically most meaningful. 
Th e result revealed the deterministic role of such threshold in defi ning the core size. If we 
required for a taxon to be present in all participants at high abundance, then the size of the 
common core microbiota was practically zero. Hence, we included all healthy subjects of Study 
II (n=9) in the analysis and utilized the full detection range of the phylogenetic microarray, 
including also phylotypes with a low abundance (minimum relative abundance 0.05%), while 
covering a large dynamic range. By using this detection threshold and requirement for 100% 
prevalence we concluded that the core microbiota of 9 healthy subjects consisted of 288 species-
like taxa representing about 40% of the detected phylotypes. Th e common core microbiota 
mainly included members from the Firmicutes phylum, specifi cally bacteria related to R. obeum, 
F. prausnitzii, and O. guillermondii but there were also phylotypes from the other major phyla, 
Actinobacteria and Bacteroidetes. However, the abundance of these latter phylotypes varied 
greatly from subject to subject. When combining the data from all healthy subjects of this thesis 
and computing the core microbiome we could conclude that the core contained 208 phylotypes 
and was dominated again with Firmicutes from the Clostridium clusters IV and XIVa (Figure 4). 
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Figure 4: Common microbial core from 54 healthy subjects studied in this thesis. A) 
Showing the continuum of the core. Its size varies depending on the prevalence and analysis 
depth. B) Composition of core with maximum prevalence and lowest detection threshold. 
Th e estimation of core microbiota as a continuum of prevalence and abundance, introduced 
in Study II, has been followed-up in a large-scale study involving 115 healthy individuals 
(Salonen et al., 2012). Th ey verifi ed our initial fi ndings of the core size and its composition and 
could not detect any core taxa with a relative abundance over 2.5%, indicating that the abundant 
taxa vary between individuals. However, when setting the detection limit to 0.05% of the relative 
abundance, the common core of these 115 healthy individuals included 30% of all detected 
phylotypes. 
In addition to the common core composition, we assessed the temporal stability of the 
shared phylotypes, since this had not been addressed in previous studies. Th e majority (70%) 
of the core phylotypes fl uctuated by less than 10% during the 7-week study period. Th e high 
temporal stability of the individual core could suggests a strong selection by the healthy host 
for a particular microbial composition, but the temporal fl uctuation of certain taxa, such as 
Bacteroidetes (Eckburg et al., 2005), partly explains the lack of phylotypes from these genera 
in the core analysis. Previous fi ndings either supported (Sekelja et al., 2011; Tap et al., 2009; 
Turnbaugh et al., 2009) or contradicted (Claesson et al., 2010; Qin et al., 2010; Willing et al., 2010) 
our fi ndings of low numbers of Bacteroidetes in the core microbiota. Th ere are various reasons to 
explain this fi nding, including several technical issues, such as choice of DNA extraction method 
and its eff ect on the relative share of Bacteroidetes (Study I) as well as the depth of the sequencing 
analyses. Other factors such as subjects’ age, nationality and diet may eff ect the obtained results, 
but there are presently too few data to address these in a coherent way. 
Th e core microbiota identifi ed in Study II contained more phylotypes than formerly 
reported. Th e previous estimations of the size of the common microbial core size have varied 
from a few percentages (Turnbaugh et al., 2009) to over 30% (Huse et al., 2008; Qin et al., 2010). 
Th e within-subject temporal variation of certain taxa could be one of the reasons why the 
commonly core microbiota have not been detected in some of the previous studies. However, 
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with a analytical method able to detect low abundant species, accommodating the large 
individual variation, the core microbiota of healthy subjects could be addressed. In our study, the 
use of phylogenetic microarray facilitated the detection of the core microbiota as the microarray 
has a low detection threshold and only quantifi es the fi xed set of previously known phylotypes, 
minimizing the overall variation in microbiota profi les. Taxa with a relative abundance as low as 
0.05% are not readily detectable with the NGS approaches, hence they may well have remained 
undetected in the previous studies (Claesson et al., 2010; Qin et al., 2010).
5.2.3  MILD INTESTINAL SYMPTOMS ASSOCIATED WITH MICROBIAL 
COMPOSITION
It is very common for healthy individuals to occasionally experience intestinal discomfort.  A 
survey mapping the prevalence on intestinal complaints in healthy Finnish adults (n=46), revealed 
that the most frequent intestinal symptom was fl atulence, experienced at least weekly by 66% of 
the healthy subjects (Jalanka, unpublished data). Moreover, 29% of the participants experienced 
intestinal pain at least monthly (Figure 5). Th erefore, not surprisingly the participants of Study 
II, though in good general health, experienced occasional, mild intestinal complaints throughout 
the study period (Study II, Table 1). Th e most frequent complaints were mild to moderate 
feelings of abdominal bloating or pain. We aimed to fi nd correlations between the intestinal 
complaints and the intestinal microbiota composition. We identifi ed a signifi cant positive 
association between bloating and the abundance of uncultured bacteria related to Anaerotruncus 
colihominis and Ruminococcus callidus (p<.05). Both have been associated previously with rumen 
microbiota and cellulose fermentation (Li et al., 2012). Th is process is known to produce both H2 
and CO2 and hence could explain the observed association with bloating. Moreover, previously 
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Figure 5: Commonly experienced intestinal symptoms recorded from 46 healthy subjects 
participating in a science outreach.
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the bacterial overproduction of H2 has been claimed to contribute to intestinal symptoms in 
healthy subjects (Kleessen et al., 2007). Other phylotypes with signifi cant associations to bloating 
included uncultured relatives of Ruminococcus fl avefaciens (p<.05). Th e abundance of these R. 
fl avefaciens-like bacteria was elevated in individuals with increased perception of symptoms. R. 
fl avefaciens is an anaerobic bacterium, known to obtain nutrients by breaking down cellulose 
resulting in the production of organic acids, acetate as well as CO2 and H2 (Julliand et al., 1999). 
Th e other frequently recorded symptom among the subjects was abdominal pain, which 
correlated with several phylotypes from the Bifi dobacterium genus, but also a phylotype from the 
genus Tannerella. Th e latter was also associated in Study IV with the IBS-type microbiota and 
increased mucosal expression of pro-infl ammatory tumor necrosis factor (TNF) pathway (Study 
IV, Figure 3). In Study II, the subjects experiencing abdominal pain had 6-fold less bifi dobacteria 
than subjects with no pain (p<.05). Th ese results were verifi ed with qPCR and provide further 
correlation-based evidence for the impact of bifi dobacteria on intestinal health. 
Th e inverse correlation between bifi dobacterial abundance and abdominal pain was a 
novel fi nding in healthy adults but has been previously but less pronouncedly reported in IBS 
patients (Malinen et al., 2010; Tana et al., 2010) and in IBS patients consuming probiotics with 
bifi dobacterial species (Guglielmetti et al., 2011; Whorwell et al., 2006). Several studies have 
reported decreased levels of bifi dobacteria in IBS patients (reviewed by (Salonen et al., 2010) 
and a probiotic B. infantis is documented to reduce visceral pain both in mice (McKernan et al., 
2010) and humans (Brenner et al., 2009). On the other hand, there is also a study in IBS patients 
where the decrease of bifi dobacteria coincided with decreased the experienced GI symptoms 
during a FODMAP (Fermentable, Oligo-, Di-, Mono-saccharides and Polyols) restriction diet 
(Staudacher et al., 2012). However, the reduction of bifi dobacteria in that study was likely due to 
the reduced intake of bifi dogenic fi bres during FODMAP restriction rather than being causally 
associated to the reduced symptoms of fl atulence, bloating and pain, as bifi dobacteria do not 
produce gas during growth.  
5.3  PERTURBATIONS TO THE HEALTHY MICROBIOTA – THE EFFECT OF 
BOWEL CLEANSING (STUDY III)
Th e stability of the intestinal microbiota in a healthy subject is high and resilient to change since 
it has been shown to recover back to its original composition relatively rapidly aft er perturbations 
(Study II). Bowel cleansing introduces an osmotic fl ow of fl uids into the intestine reducing 
the amount of luminal bacteria, introduces oxygen (Strocchi et al., 1990) into an anaerobic 
environment, and reduces the amount of available nutrients. All of these changes are likely to 
aff ect the microbial ecosystem. 
One of the main objectives of the bowel cleansing procedure is to clear the intestinal tract 
from faecal material as well as from its microbial content prior to colonoscopy or gastric surgery. 
Although the eff ectiveness and safety of this procedure has been extensively characterized 
(Connor et al., 2012), very little is known about its eff ects on the intestinal microbiota. Study 
III aimed to address this aspect of lavage and, moreover, to determine whether diff erent doses 
of a purgative would cause long-lasting eff ects in the recovery rate of the microbiota. A total 
of 23 healthy subjects were randomly assigned into groups receiving two litres of the laxative 
in two diff erent dosage protocols (Garsed et al., 2012). One group consumed a split dose of the 
study substance where the fi rst litre was consumed in the evening and the second taken in the 
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following morning. Th e other group consumed the 2 litres of the PEG solution as single dose in 
the morning of the study. Four consecutive stool samples were collected; at baseline, immediately 
aft er the lavage and two follow-up samples 14 and 28 days aft er the bowel cleansing. 
5.3.1  THE EFFECT OF BOWEL CLEANSING ON THE INTESTINAL MICROBIOTA 
COMPOSITION 
It has been shown that the best result in bowel cleansing prior gastric operation is achieved 
by using a split dose over a single, larger dose of the purgative (Cohen, 2010). However, the 
eff ectiveness of the two diff erent doses on the microbiota had not been addressed previously, 
though this procedure is widely used in clinical practice. In this study, both doses of the 
purgative signifi cantly reduced the total bacterial amount quantifi ed at the point of lavage 
(p<.05). However, the split dosing introduced a higher reduction to the total microbial load than 
observed with the single dose procedure. Since one of the main aims of the bowel cleansing is 
to reduce the microbial load (Strocchi et al., 1990), the split dosing procedure was a superior 
method in that respect.
To investigate the individual diff erences in the microbial perturbation and recovery, 
we performed a hierarchical clustering of the total microbial profi les. Th e composition of the 
intestinal microbiota is very subject-specifi c, which results in the unsupervised grouping of 
consecutive samples from the same individual in a hierarchical clustering analysis (Study II) 
(Rajilic-Stojanovic et al., 2012). In this cohort, in 5 out of 23 (22%) subjects, the sample taken 
immediately aft er lavage did not cluster with the earlier sample from the same individual, 
indicating that the composition was drastically altered. However, already 14 days aft er the lavage 
the microbial composition of these subjects had returned its original state and resembled the 
baseline sample with 94% similarity. Th is indicated that the majority of the microbiota returned 
to its original composition aft er the laxative treatment, although the lavage introduced a transient 
dramatic change.
5.3.2  CHANGES IN THE INTESTINAL MICROBIOTA COMPOSITION IMMEDIATELY 
AFTER LAVAGE 
Consumption of laxatives is known to increase the water content in the intestine resulting 
into removal of the luminal content and faecal material (Strocchi et al., 1991). Accordingly, we 
observed a large, 31-fold reduction of the total microbial load caused by the laxative treatment 
as well as changes in the faecal microbiota composition. Samples collected immediately aft er 
the lavage were signifi cantly diff erent when compared to the baseline (p<.05), according to the 
mean relative abundances of genus-like phylogenetic groups. Th e levels of bacteria affi  liated to 
the Bacilli and Clostridium cluster IV were signifi cantly decreased at the point of lavage (p<.05). 
Th e latter included abundant butyrate-producing bacteria related to F. prausnitzii as well as 
less known and so far uncultured representatives of Oscillospira guillermondii. Interestingly, 
we also noted that the proportion of some members of the Clostridium cluster XIVa increased 
(bacteria related to R. obeum and Dorea formicigenerans) in addition to the increase of several 
Proteobacteria (all p<.05). 
 Th e GI tract contains high levels of endogenous and exogenous proteases (Antalis 
et al., 2007). Th ese enzymes are involved in the breakdown of proteins as well as in the 
regulation of several other cellular processes such as cell-cycle progression, cell death and DNA 
replication (Turk, 2006). Elevated levels of faecal serine proteases (FSP) are detected in some 
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IBS patients, and are considered to increase the intestinal permeability and potentially lead to 
visceral hypersensitivity (Gecse et al., 2008). In this study, the laxative treatment resulted into 
momentary increased levels of FSP, previously shown to be of pancreatic origin (Tooth et al., 
2013). To determine whether the elevated FSP could be associated to compositional changes of 
the intestinal microbiota, we correlated the bacterial taxa with the sudden change in the FSP 
levels. Th e strongest correlations were observed between bacteria related to F. prausnitzii (r=-
0.40), whose levels decreased during the lavage, in addition to the positive association detected 
between bacteria related to D. formicigenerans and FSP (r=0.45).  Our fi ndings are in line with 
a recent report where the increased FSP amounts were associated with lowered amounts of F. 
prausnitzii (Carroll et al., 2013). It has been shown in experimental rat studies that the majority 
of the secreted FSP is degraded by the intestinal bacteria (Genell and Gustafsson, 1977). 
Hence, the correlation of FSP amounts with reduced counts of important bacterial groups as F. 
prausnitzii suggests that having normal levels of such bacteria ensures an adequate degradation 
of endogenous pancreatic protease thus avoiding sensitisation of the rectum. 
5.3.3  IMPACT OF DIFFERENT DOSES OF THE LAXATIVE TREATMENT ON THE 
MICROBIOTA
One aim of this study was to evaluate whether dosing of the purging agent would aff ect 
recovery of the microbiota aft er the laxative treatment. When analysing the diff erences in the 
abundance between the baseline and follow-up samples, we identifi ed taxa from 5 diff erent 
genera to be statistically signifi cantly diff erent 14 or 28 days aft er the ingestion of PEG solution 
(p<.05). Th ere was a 19% overall increase in all of the involved bacteria. Specifi cally, there 
was increase in Clostridial species related to D. formicigenerans as well as an increase in the 
facultative aerobic bacteria belonging to Fusobacteria and Proteobacteria, indicating that these 
potentially pathogenic bacteria had increased in abundance aft er the bowel cleansing. Th ese 
organisms, although all part of the normal microbiota, harbour pathogenic potential and their 
increased abundance have been associated with adverse health outcomes (Chow et al., 2011). 
Th e increased abundance of phylotypes related to D. formicigenerans has been described in 
IBS (Rajilic-Stojanovic et al., 2011), Ulcerative colitis (Nomura et al., 2005) as well as in non-
alcoholic fatty liver disease (Raman et al., 2013). Similarly, Fusobacteria and Proteobacteria are 
Gram-negative bacteria oft en implicated in infl amed intestinal tissue (Swidsinski et al., 2011). 
Although the increase of these potential pathogens might not have any health implications in 
healthy individuals, in conditions involving decreased microbiota diversity the increase in 
these potential pathogens could be more substantial and their metabolic products may evoke to 
intestinal symptoms or health impairment.
It has been claimed that the split dose of PEG solution is superior to the single dose in 
the bowel cleansing with an osmotic laxative treatment (Cohen, 2010). Th e present microbiota 
results support these fi ndings. On the day of lavage, there was a signifi cantly higher reduction 
in the total bacterial counts with the split dose treatment as compared to that achieved with the 
single dose. Moreover, there was a higher microbiota recovery with the split dose treatment than 
with the single dose, where the bacterial phyla such as Proteobacteria remained elevated and 
did not return to their original levels aft er 28d of consumption of the purgative (Figure 6).  In 
conclusion, the split dose of the laxative has a less disturbing eff ect on intestinal microbiota than 
a single dose. 
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Figure 6: Th e microbial recovery of the Proteobacteria phyla calculated as the correlation of the 
microbial profi le against the baseline sample, in the two dosing groups. Statistical signifi cance is 
indicated with an asterisk.
5.4  PERTURBATIONS TO THE HEALTHY MICROBIOTA  - 
MICROBIAL CHANGES IN POST-INFECTIOUS IRRITABLE BOWEL 
SYNDROME (STUDY IV)
Th e aim of this study was to characterize diff erences in the microbial composition of PI-IBS 
patients with varying degrees of symptoms, and to address the associations between the 
faecal microbiota and the clinical features of IBS. As the development of IBS is multifactorial, 
we hypothesized that the observed symptoms and development of PI-IBS may arise from the 
interplay between the faecal microbiota, the host immune response, and psychological factors. In 
order to fi nd these associations we conducted a detailed characterization of the faecal microbiota 
of patients in diff erent degrees of recovery from gastroenteritis and compared these to healthy 
controls and patients with IBS-D.
5.4.1  THE INDEX OF MICROBIAL DYSBIOSIS 
We hypothesized that instead of limiting the comparative microbiota analysis to individual 
taxa, it would be relevant to search for a microbial signature that potentially diff ers between the 
patients and healthy controls. By using a bioinformatic approach that allowed this, we identifi ed 
a combination of 27 genus-like groups that separated the study groups (Figure 7). Th e microbial 
profi le of the PI-IBS and PI-BD groups resembled those of the IBS-D patients. Th e major 
diff erence in the patients’ microbiota was the 12-fold increase of Bacteroidetes phylum and the 
35-fold decrease of Uncultured Clostridia from the Firmicutes phylum. Furthermore, when 
all participants were indexed according to the abundance of the discriminating bacterial taxa 
(Figure 7), a specifi c ordering of the study subjects was obtained, refl ecting their health status, a 
so called index of dysbiosis (IMD).
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Figure 7: Index of microbial dysbiosis (IMD) was created using Bootstrap aggregated 
Redundancy analysis (RDA) of the microbiota composition showing the bacterial groups 
signifi cantly contributing to separation between the healthy controls and the patient groups. 
Th e position of each study subject in the plot was transposed on the fi rst axis of the RDA, 
which explains the majority of the microbial separation, creating an index of microbial 
dysbiosis (IMD).
When the Firmicutes/Bacteroidetes ratio was measured, there was a signifi cant decrease 
in the PI-IBS group when compared to all of the healthy controls examined in the thesis work 
(p<.05,  unpublished data, Figure 8). Th e increase of  Bacteroidetes. was confi rmed with qPCR 
of the Bacteroides-Prevotella-Porphyromonas-group. Interestingly, similar microbiota changes 
have been associated with susceptibility of enteric pathogens (Haag et al., 2012). It was thought 
that the infection predisposition of an individual could increase due to a certain microbial 
composition, since the complex interactions between the microbiota and host immune system 
might expose certain individuals to gastroenteric episodes.
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Figure 8: Amounts of Firmicutes and Bacteroidetes in the patient groups and healthy 
controls. Relative abundance of Firmicutes is shown with turquoise and the relative amount 
of Bacteroidetes shown in red. A Statistically signifi cant diff erence when compared to 
healthy controls is indicated with an asterisk.  
Th e role of Bacteroides ssp. in the aetiology or pathophysiology of IBS is unclear. Previous 
studies have reported opposing results regarding the relevance of Bacteroidetes in IBS patients. 
Some have reported increased amounts of Bacteroides spp. in patients with IBS (Kassinen et al., 
2007; Parkes et al., 2012; Ponnusamy et al., 2011) and also in related functional bowel disorders, 
(Manichanh et al., 2013) whereas others have detected a higher abundance in healthy controls 
(Jeff ery et al., 2012; Krogius-Kurikka et al., 2009; Rajilic-Stojanovic et al., 2011). Explanations to 
the discrepancy are many, but such extensive variation in the microbiota fi ndings may suggest 
that rather than a single pathobiont, it is the altered microbial community as such that is the 
important factor in the pathophysiology of IBS. Changes in the host might trigger the observed 
changes as for example accelerated transit is known to modify the microbiota (Kashyap et al., 
2013a) and Study III). Currently, it cannot be clearly stated whether the microbiota change is the 
cause of IBS or whether it is secondary to IBS pathophysiology.
Previous studies have shown that the microbial composition of IBS patients could be used 
to further stratify IBS patients and thus complement the clinical subgroupings (Jeff ery et al., 
2012). Our analysis on the patients in the post-infectious subcategories of this cohort verifi ed 
these previous fi ndings. We tested the clinical signifi cance of the IMD by correlating it with the 
diagnostic variables of IBS patients and found positive associations with the IBS-type microbiota 
and several intestinal complaints. However, there were no signifi cant correlations with the 
psychological symptoms oft en associated wit IBS. Th is was also replicated with another cohort 
where IBS patients with a microbial profi le similar to healthy controls had signifi cantly more 
psychological problems than the IBS patients with an altered microbiota (Jeff ery et al., 2012). 
Th erefore, it could be speculated that the IBS patients with an altered microbiota and those 
with psychological symptoms have diff erent disease aetiology. Together, these results indicate 
that the discriminant microbial profi le could be used as an objective measure of disturbed bowel 
functions and a potential novel way of stratifying this heterogeneous patient material.
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 Th e putative associations between the discriminant microbiota and host responses 
were determined by mapping the gene expression data derived from rectal biopsies to known 
biological functions using Gene Set Analysis (GSA), as well as other clinical measurements 
refl ecting infl ammatory responses. Th e IMD correlated positively with several host expression 
pathways associated with infl ammation as well as with increased cytokine production, whereas 
the patient disease status or separate microbial abundances alone did not show any signifi cant 
associations. 
5.4.2  ASSOCIATIONS BETWEEN MICROBIOTA AND HOST GENE EXPRESSION 
To further analyse the host – microbiota crosstalk we concentrated on the 27 taxa of IMD and 
separately studied their associations between the host expressional changes. Th ere were several 
independent measures linking the abundance of the IBS-type microbiota to changes in the host 
gene expression. We identifi ed associations between the discriminant microbiota and the physical 
barrier integrity of the host. Th e most prominent negative correlation was observed between 
seven Bacteroidetes ssp. and the expression of glycine, serine, threonine metabolism pathway. It is 
known that majority of the dietary threonine is utilized for synthesizing the secretory mucin and 
that its dietary restriction results in the impaired gut barrier (Faure et al., 2005).  In general, these 
amino acids are known to be important in the maintenance of gut integrity and the effi  cacy of 
the mucin layer (Hansson, 2012). Fucosyltransferase-2 is involved in the formation of the ABO 
blood groups and also acts as an adhesion receptor for several microbes (Moulds et al., 1996). It 
has been claimed that it is the mucus structure and the extent of the glycosylation, which shapes 
the microbiota composition (Wacklin et al., 2014). Fut2 defi cient mice (Fut2−/−) have been shown 
to display diff erences in microbial diversity and the community composition as they harbour 
increased amounts of several Bacteroides species and increased levels of Clostridiales (Kashyap 
et al., 2013b). Moreover, conditional knock-out mice lacking the enzyme responsible for 
o-glycosylation in mice, core 1 β1,3-galactosyltransferase (C1galt1) presented subtle changes in 
their intestinal microbiota composition, where Bacteroidetes was increased and the Firmicutes 
were reduced (Sommer et al., 2014). 
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Figure 9: Proposed model for the development of symptoms in post-infectious IBS patients. 
Modifi ed from Simren, 2014.
Additionally to the alterations in the expression of glycine, serine, threonine metabolism 
pathway, there were several other pathways associated with the IMD bacterial taxa and cell 
junctions, or cell junction integrity as well as the pathways indicating increased infl ammatory 
response (see Figure 3 from Study IV). Based on these fi ndings, our hypothesis is that the 
physical barrier of subjects with IBS-type microbiota has been compromised resulting in a low-
grade infl ammation, a typical symptom of IBS patients. Moreover, we could show that the IMD 
correlated with the IBS symptoms and clinical features whereas in the patients with a more 
psychological basis for the disease, the eff ect of microbial dysbiosis was smaller (Figure 9). 
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6.  CONCLUSIONS AND FUTURE ASPECTS
Th e work presented in this thesis represents new knowledge in the fi eld of intestinal microbiota 
research from several diff erent aspects. We addressed a source of technical biases in the 
microbiota research and validated an effi  cient faecal bacterial DNA extraction method. Moreover 
the characteristics of the healthy intestine were benchmarked and compared with two common 
perturbations. Our study on IBS was among the fi rst to perform an integrated analysis of the 
diff erent aspects of the disease aetiology allowing us to obtain a holistic view of the patients and 
to identify several novel associations between the intestinal microbiota and the host’s clinical 
status. 
Th e Study I was focused on fi nding an optimal DNA extraction procedure to be used 
throughout the thesis. Th e optimal extraction protocol, repeated bead-beating (RBB), achieved 
the highest diversity and high DNA extraction effi  ciency, especially its ability to extract DNA 
from methanogens as well as Clostridium cluster IV phylotypes was superior. Our study 
was pioneering in that it was one of the fi rst to exploit community-wide microbiota analyses 
comparing diff erent DNA extraction protocols. Our results emphasized the importance of 
pre-analytical steps in the microbiome research. Recently an on-going, large comparative trial 
evaluating several DNA extraction procedures ranked the RBB method one of the top three 
faecal DNA extraction protocols (personal communication with Anne Salonen and Joel Dore, 
IHMS, 2012). Th is project validated our results, and responds to the high need for standard 
operating procedures in human microbiome research. Standardized methodology on all of the 
analysis steps, from sample collection and storage to DNA extraction and analysis pipelines is 
imperative for the effi  cient use of rapidly cumulating data as it enables meta-analyses and can 
provide a more holistic and conclusive view of the intestinal microbiota properties.
Th e characteristics of the healthy intestinal microbiota were addressed in Study II. We 
showed that the microbiota of a healthy adult possessed high individuality remains stable 
during consecutive weeks and was resilient to change. By studying the bacteria shared by most 
of the studied individuals, we determined a common microbial core. Additionally we observed 
associations between microbiota composition and common intestinal symptoms giving a 
novel insight in the potential functions of specifi c taxa such as bifi dobacteria. Altogether, these 
fi ndings provide new approaches to defi ne intestinal health and to characterize the microbial 
communities inhabiting the human gut. 
It has been shown that the function and composition of the intestinal microbiota of healthy 
subjects correlate with each other. Th e microbial composition displays high individual variation 
whereas the functions of the microbiota have been shown to be fairly constant (Huttenhower 
et al., 2012). Th is indicates that the key functions for health performed by the microbiota can 
be carried out by various diff erent phylotypes and that the function is more relevant to health 
rather than “who” performs it. Th erefore, the future research should focus on determining the 
diff erences in the microbial functions in health and disease and aberrations possibly contributing 
to disorders.  Since the microbiome is also transcriptionally regulated, it would be important 
to conduct more studies on the metatranscriptomics and metaproteomics to obtain a more 
comprehensive view on the capacity of the microbiota. Currently very few studies utilizing this 
technique (Booijink et al., 2010; Gosalbes et al., 2011; Perez-Cobas et al., 2013) due to several 
challenges, such as the instability of RNA and a small amount (2%) of messenger RNA (Morgan 
and Huttenhower, 2014). 
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Th e microbiota of healthy subjects were further benchmarked against perturbations, 
induced osmotic diarrhoea and a disease state IBS. Bowel cleansing is a standard procedure prior 
to colonoscopy or gastric surgery. Oft en the aim is to reduce the amount of intestinal microbiota 
to avoid bacterial complications. Th e results of Study III showed that the split dosing of the 
purgative agent reduced the total bacterial load signifi cantly more when compared to the single 
dose. Moreover, there were signifi cant diff erences in the recovery rates of certain bacterial groups 
between the two diff erent doses. Bacterial genera including potential pathogens were increased 
in healthy subjects when the single dose approach was applied. No such similar phenomenon 
was detected with the double dosing regime. Our results provide novel insight into the eff ects of 
purgative agents on the patient and may become incorporated into the clinical practice via the 
recommendation to split the purgative treatment into two dose administrations. However, our 
present results were conducted in healthy individuals. Patients requiring colonoscopy or gastric 
surgery oft en have an underlying disease, such as infl ammatory bowel disease or colon cancer, 
both conditions known to be associated with unstable microbiota (Table 4). Th e eff ects of bowel 
cleansing on the host will need to be tested in these patient groups separately, in order to achieve 
a better understanding of the eff ects of purging on their health.
Th e relevance of microbiota in the pathophysiology of IBS was addressed in Study IV. We 
could show that a group of 27 bacterial taxa separated the post-infected and the IBS patients 
from healthy control. Moreover, this index of microbial dysbiosis could be associated to 
gastrointestinal symptom severity, and clinical markers, allowing stratifi cation of patients on 
the basis of the IMD. Interestingly the severity of anxiety or depression did not correlate with 
the microbial changes. Th e applicability of the IMD for stratifi cation of the patient material 
should be tested in another, larger cohort containing both PI-IBS patients as well as other IBS-
subtypes. Th e aim of this trial would be to validate the diagnostic potential of IMD species and 
development of a fast method for the detection of their abundance. Currently, the diagnosis and 
stratifi cation of IBS patients relies greatly on subjective and symptom based diagnosis. Objective 
markers are mainly used to exclude other, more severe diseases. Th e intestinal microbiota could 
be used to further stratify patients, i.e. diff erentiating those with a psychological rather than 
organic cause. Th us, it would be highly relevant for both patients as well as for further research. 
Study IV also focused on fi nding host-microbiota interactions in IBS patients. It identifi ed 
several cellular pathways, such as protein metabolisim and cell junction expression pathways 
to be decreased when the levels of IMD species were increased. Th is work could be used as a 
starting point for future functional studies where both host and microbiota functional responses 
would be addressed. Th e eff ect of the aberrations in the microbiota could be tested in animal 
models such as gnobiotic rodents. Such studies have already revealed that IBS symptoms could 
be transferred with the microbiota suggesting a causal link between the microbiota dysbiosis 
and symptom development (Crouzet et al., 2013). However, in these studies the dysbiosis has 
been caused by diff erent set of taxa therefore the relevance of the IMD species should be verifi ed 
this in similar animal experiments, to confi rm the eff ect of the observed dysbiosis. Moreover the 
signifi cance of health related strains could be potentially tested in human trials. One example 
would be the supplementation of a novel, potential probiotics F. prausnitzii, which have been 
shown to be signifi cantly decreased or even absent in IBD patients in remission (Fujimoto et 
al., 2013; Varela et al., 2013). Th erefore the re-establishment of these phylotypes could be 
benefi cial for these patients. However, due to the complexity of the microbiota, the eff ects of a 
single strain may only be moderate. Th erefore, restoring the healthy microbiota composition via 
faecal microbial transplants (FMT) could be more effi  cient and benefi cial to the patient. Th ere is 
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very promising evidence of the positive eff ect of FMT in from patients with antibiotic induced 
Clostridium diffi  cile infection (van Nood et al., 2013) and has been used to treat also other GI 
disorders, for example IBD (Brandt and Aroniadis, 2012) as well as non-GI disorders such as 
multiple sclerosis (Borody et al., 2011).
Several health and disease related taxa identifi ed in this thesis represent uncharacterized, 
so far uncultured phylotypes. One of the most consistent markers of IBS, detected in several 
independent cohorts including study IV, is the uncultured bacterium related to Ruminococcus 
torques. It would be highly relevant for future research and patient care to characterise this 
as well as several other uncultured phylotypes important for health. For example, Study IV 
demonstrated that the healthy subjects had 35-fold more uncultured Clostridiales than the post-
infectious or the IBS patient groups. Th erefore, it would be relevant to culture and characterise 
this group of bacteria. 
Th e temporal stability of the healthy microbiota was covered in Study II, however no large-
scale studies have been conducted in IBS patients with similar extensive follow-up to study 
the temporal fl uctuations of the patient microbiota. It is very common for the IBS patient to 
experience day-to-day fl uctuations in their symptoms, and the basis for this feature is unknown 
(Cremonini and Talley, 2005). Temporal instability of the patients’ microbiota could alter the 
physiology of the host and thus provide insight in the symptom fl uctuation, characteristic of IBS 
patients. Moreover, repeated sampling of IBS patients during and between the symptom episodes 
would make it possible to investigate whether the discrepancy of the IBS-related microbial 
changes in the current literature could be partly attributed to the large temporal variation in 
symptom occurrence.
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